var title_f25_31_26096="Location of Koch's triangle";
var content_f25_31_26096=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F52196&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F52196&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Koch's triangle and fast and slow pathways",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 389px; height: 276px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schematic representation of Koch's triangle which is bounded by the tricuspid ring and the tendon of Todoro. The tendon of Todoro and the tricuspid ring are in close proximity forming the apex of the triangle near the His bundle at the membranous septum. Koch's triangle can be divided into thirds: the anterior contains the compact AV node; the posterior contains the coronary sinus; and the middle or mid-septal third is between the anterior and posterior portions. The anterior third is associated with fast pathways, and the middle and posterior thirds with slow pathways.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_31_26096=[""].join("\n");
var outline_f25_31_26096=null;
var title_f25_31_26097="Tretinoin APL differentiation";
var content_f25_31_26097=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F66640&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F66640&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Acute promyelocytic leukemia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 384px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    During treatment with tretinoin, malignant promyelocytes in acute promyelocytic leukemia (APL) begin to differentiate to neutrophils. The cells acquire secondary granules, and the nuclear chromatin becomes condensed.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Richard A Larson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_31_26097=[""].join("\n");
var outline_f25_31_26097=null;
var title_f25_31_26098="Subungual melanoma - advanced";
var content_f25_31_26098=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F75881&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F75881&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Subungual acral lentiginous melanoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 323px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Destruction of the nail bed by the tumor is present in this patient with subungual melanoma involving the toe. Note the presence of pigment involving the periungual skin (Hutchinson's sign).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_31_26098=[""].join("\n");
var outline_f25_31_26098=null;
var title_f25_31_26099="Tympanic membrane anatomy";
var content_f25_31_26099=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F57110&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F57110&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Anatomy of the tympanic membrane",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 393px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schematic of a right tympanic membrane indicating the quadrants. A line drawn along the manubrium (or \"handle\") of the malleus divides the tympanic membrane into anterior and posterior halves. A line drawn through the umbo (perpendicular to the first line) divides the tympanic membrane into superior and inferior halves.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_31_26099=[""].join("\n");
var outline_f25_31_26099=null;
var title_f25_31_26100="Tinea cruris buttocks";
var content_f25_31_26100=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F76169&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F76169&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Tinea cruris, involvement of buttocks",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 285px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This patient with tinea cruris exhibited extension of disease to the buttocks and gluteal cleft.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Goodheart, HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_31_26100=[""].join("\n");
var outline_f25_31_26100=null;
var title_f25_31_26101="Intrauterine adhesions";
var content_f25_31_26101=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Intrauterine adhesions",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/31/26101/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/31/26101/contributors\">",
"     Marcelle I Cedars, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/31/26101/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/31/26101/contributors\">",
"     Robert L Barbieri, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/31/26101/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/31/26101/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/31/26101/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intrauterine adhesions develop as a result of intrauterine trauma. The degree of adhesion formation and the impact of the adhesions on the contour of uterine cavity vary greatly. With minimal disease, thin bands of tissue stretch between surfaces of the uterine cavity, whereas severe disease is characterized by complete obliteration of the cavity, with the anterior wall of the uterus densely adherent to the posterior wall.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 90 percent of cases of severe intrauterine adhesive disease are related to curettage for pregnancy complications, such as missed or incomplete abortion, postpartum hemorrhage, or retained placental remnants [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26101/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Repeated curettage for pregnancy loss increases the risk of developing adhesions from 8 percent after the first curettage to over 30 percent with the third curettage [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26101/abstract/3\">",
"     3",
"    </a>",
"    ]. The basalis layer of the endometrium appears to most susceptible to damage in the first four postpartum or postabortal weeks; however, adhesions can develop in the nongravid uterus as a result of endometrial injury from procedures such as myomectomy or nonpuerperal curettage [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26101/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The role of postpartum or postabortal infection in adhesion formation is controversial, and data are limited. A study that evaluated 28 women with significant postcesarean delivery endometritis by hysteroscopy reported the frequency of adhesions in these women was similar to that in controls without postcesarean infection [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26101/abstract/5\">",
"     5",
"    </a>",
"    ]. Another study reported a nonsignificant increase in adhesion formation when dilation and curettage was performed in the presence of concurrent infection [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26101/abstract/6\">",
"     6",
"    </a>",
"    ]. Trauma is the major cause of intrauterine adhesions, although infection may play a minor contributing role.",
"   </p>",
"   <p>",
"    In the developing world, genital tuberculosis is a cause of intrauterine adhesions, which are often severe with complete obliteration of the uterine cavity [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26101/abstract/7\">",
"     7",
"    </a>",
"    ]. These patients typically present with primary amenorrhea and cyclic pelvic pain. The adhesions are believed to form secondary to chronic inflammation of the endometrium. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/11/39097?source=see_link\">",
"     \"Postpartum endometritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intrauterine adhesions can be asymptomatic and of no clinical significance. Symptoms associated with clinically significant intrauterine adhesions include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Infertility",
"     </li>",
"     <li>",
"      Menstrual irregularities (hypomenorrhea, amenorrhea)",
"     </li>",
"     <li>",
"      Cyclic pelvic pain",
"     </li>",
"     <li>",
"      Recurrent pregnancy loss.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Infertility is the most common reason patients present for evaluation: 43 percent of women with intrauterine adhesions have some degree of infertility [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26101/abstract/2\">",
"     2",
"    </a>",
"    ]. Menstrual irregularities are also a common presentation; however, the extent of adhesions seen on hysteroscopy does not correlate well with degree of menstrual irregularity and nearly 40 percent of patients with adhesions documented on hysteroscopy report no menstrual irregularities [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26101/abstract/3\">",
"     3",
"    </a>",
"    ]. Amenorrhea (the absence of menses) due to intrauterine adhesions was first described in 1894. The disorder was further defined by Asherman in 1948 and 1950, and thus is often referred to as Asherman's syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26101/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Diagnostic evaluation is indicated in women who develop infertility, menstrual disorders, cyclic pelvic pain, or recurrent pregnancy loss, especially in the setting of previous pregnancy related curettage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis is based upon visualization of intrauterine adhesions either directly by hysteroscopy, or indirectly by imaging.",
"   </p>",
"   <p>",
"    The gold standard for the diagnosis of intrauterine adhesions is diagnostic hysteroscopy (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef72065 \" href=\"UTD.htm?11/51/12080\">",
"     image 1",
"    </a>",
"    ). An advantage of this approach is that once identified, adhesions can then be surgically resected via the hysteroscope. This allows diagnosis and treatment in a single procedure and decreases the probability of trauma to the surrounding endometrium compared to blind adhesiolysis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26101/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/17/9498?source=see_link\">",
"     \"Overview of hysteroscopy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The sonohysterogram, hysterosalpingogram (HSG), or transvaginal ultrasonography (TVUS) are other diagnostic imaging tools (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef64518 \" href=\"UTD.htm?22/4/22593\">",
"     image 2",
"    </a>",
"    ). A study comparing hysterosalpingogram, sonohysterography, and transvaginal ultrasonography (TVUS) versus hysteroscopy in 65 infertile women found hysterosalpingogram and sonohysterography to be equally sensitive for diagnosing intrauterine adhesions (both detected 3 of 4 cases, sensitivity 75 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26101/abstract/11\">",
"     11",
"    </a>",
"    ]. TVUS alone appeared to have limited usefulness in this series (detected 0 of 4 cases). Another study that used hysteroscopy as the reference standard, found HSG to have a sensitivity of 81.2 percent and specificity of 80.4 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26101/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/55/40823?source=see_link\">",
"     \"Saline infusion sonohysterography\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/37/24150?source=see_link\">",
"     \"Hysterosalpingography\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Advantages of sonohysterogram are that it does not involve radiation and some clinicians are able to perform the study in an office setting. HSG, on the other hand, must be performed in a radiology suite. A potential advantage of HSG is the ability to evaluate tubal patency, if this is indicated, although newer techniques that involve infusion of a",
"    <span class=\"nowrap\">",
"     water/air",
"    </span>",
"    combination may improve assessment of tubal patency with sonohysterogram.",
"   </p>",
"   <p>",
"    With TVUS, highly experienced ultrasonographers have reported sensitivities of 80 to 90 percent for diagnosis of intrauterine adhesions with TVUS (detected 8 of 10 cases [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26101/abstract/13\">",
"     13",
"    </a>",
"    ] and detected 10 of 11 cases [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26101/abstract/14\">",
"     14",
"    </a>",
"    ]). Given that the sensitivity of TVUS is very dependent upon the individual performing the scan, we suggest sonohysterography for initial diagnostic evaluation of these patients, rather than simple ultrasonography. Treatment must be undertaken separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/55/40823?source=see_link\">",
"     \"Saline infusion sonohysterography\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    After diagnosis, TVUS may be useful in predicting the outcome of surgical treatment of intrauterine adhesions. A study that evaluated seven women with severe adhesive disease prior to hysteroscopic resection found that women with a well-developed endometrial stripe resumed normal menses postoperatively, whereas women with minimal endometrial lining identified by ultrasound prior to surgery had an obliterated cavity, and did not respond to surgical intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26101/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adhesions can arise from the endometrium, myometrium, or connective tissue. They vary in size from thin and fragile to thick and dense, with the ends broader than the middle. They may occur at the margins of the endometrial cavity or diffusely; in severe cases they completely obliterate the cavity. Marginal adhesions may appear crescent shaped or like a curtain. Mucosal adhesions are the same color as the endometrium and fragile, whereas fibrous adhesions are pale and strong. Intrauterine adhesions due to tuberculosis tend to give the endometrial cavity a honeycomb appearance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Various classification systems for intrauterine adhesions have been proposed. The system of the American Fertility Society (now the American Society of Reproductive Medicine) consists of three stages of disease, based upon the extent of cavity involvement",
"    <span class=\"nowrap\">",
"     (&lt;1/3,",
"    </span>",
"    <span class=\"nowrap\">",
"     1/3-2/3,",
"    </span>",
"    <span class=\"nowrap\">",
"     &gt;2/3),",
"    </span>",
"    the type of adhesion seen at the time of hysteroscopy (filmy, filmy and dense, dense), and the patient's menstrual pattern (normal, hypomenorrhea, amenorrhea) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26101/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other groups have proposed alternative classification systems, but no clear consensus exists.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no randomized trials to guide therapy of these patients. Our management is based upon personal experience, small case series, and individual case reports.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Lysis of adhesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The standard treatment of intrauterine adhesions is surgery with lysis under direct visualization. This is usually performed as an ambulatory procedure using operative hysteroscopy. The goal of surgery is to restore the size and shape of the uterine cavity, as well as endometrial function and fertility.",
"   </p>",
"   <p>",
"    Care must be taken during cervical dilation in women with severe occlusion of the uterine cavity because it is easy to create false passages and perforate the uterus. Concurrent ultrasonography can help define the junction between the internal os and the intrauterine cavity, and guide dissection.",
"   </p>",
"   <p>",
"    The procedure is begun by placing the hysteroscope at the internal os and lysing adhesions with sharp dissection. We prefer to use small, rigid scissors. Adhesive bands are identified through the hysteroscope, and clipped at the junction of the band to the endometrium in order to excise the adhesion (in contrast, uterine septa are managed by incision). Careful dissection is continued until the entire uterine cavity is free of adhesions. The goal is restoration of normal anatomy. This procedure can also be performed using bipolar electrosurgery. In this technique, the adhesive bands are vaporized [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26101/abstract/16\">",
"     16",
"    </a>",
"    ]. More extensive dissection is required when there is agglutination of the walls of the cavity. In such cases, we suggest concurrent laparoscopy or ultrasound guidance to reduce the risk of uterine perforation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26101/abstract/17\">",
"     17",
"    </a>",
"    ]. Fluoroscopy can also be used in severe cases to guide dissection [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26101/abstract/18\">",
"     18",
"    </a>",
"    ]. If adhesions are so severe that the cavity cannot be entered with the hysteroscope, a laparotomy with hysterotomy is required.",
"   </p>",
"   <p>",
"    Each surgical case for this process may be quite unique and requires a careful understanding of uterine anatomy, and patient skilled dissection. With a completely obliterated cavity, dissection beginning in the midline and moving laterally under ultrasound-guidance may be effective. If there is any area of less dense adhesions that would allow visualization of normal anatomic structures (such as the cornua), dissection should begin in this area. Aggressive dissection that might enter the myometrium should be avoided.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Prevention of adhesion reformation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postoperative management is focused upon reducing the risk of reformation of adhesions. One approach is to administer high-dose estrogen therapy postoperatively to promote regrowth of the endometrium over the denuded areas created by the adhesions [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26101/abstract/1\">",
"     1",
"    </a>",
"    ]. Estrogen therapy can be started on the day after the procedure. The standard dose is 5 mg of conjugated estrogen or 8 mg estradiol, in a divided dose daily for 30 days. This is followed by a withdrawal bleed stimulated by progesterone. Progesterone is administered in the form of 10 mg daily of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/24/1417?source=see_link\">",
"     medroxyprogesterone acetate",
"    </a>",
"    , given concurrently with the last 10 days of estrogen therapy.",
"   </p>",
"   <p>",
"    Another approach is placement of a bladder catheter (eg, size 8 pediatric with a 5 cc balloon) or intrauterine device (IUD) into the uterine cavity immediately after lysis of adhesions. The IUD is removed after three months; the bladder catheter is removed from the uterus after 10 days [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26101/abstract/19\">",
"     19",
"    </a>",
"    ]. Antibiotics should be given concomitantly with the bladder catheter, as this represents a foreign body in the uterus contiguous with the non-sterile vagina.",
"   </p>",
"   <p>",
"    We suggest placement of a Foley catheter in the uterine cavity immediately postoperatively to decrease reformation of adhesions. When outcomes after Foley catheter or IUC placement were compared, use of the Foley catheter resulted in a greater proportion of women achieving normal menses (81 versus 63 percent), higher conception rates (34 versus 23 percent), and a reduced need for reoperation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26101/abstract/19\">",
"     19",
"    </a>",
"    ]. There are no good data comparing these modalities to estrogen use after hysteroscopy for lysis of adhesions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Menstruation is restored in 73 to 92 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26101/abstract/4\">",
"     4",
"    </a>",
"    ]. One study reported all 40 patients who presented with recurrent pregnancy loss were able to conceive after surgical treatment of their adhesions [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26101/abstract/20\">",
"     20",
"    </a>",
"    ]. Other series reported live delivery rates of 32 to 76 percent, with the lowest success rates among women with more severe adhesive disease",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    additional risk factors for subfertility [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26101/abstract/21-24\">",
"     21-24",
"    </a>",
"    ]. In addition, some of these pregnancies were complicated by placenta accreta, possibly related to persistent abnormalities of the endometrial surface, or complications associated with amniotic bands. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/7/8311?source=see_link\">",
"     \"Clinical features and diagnosis of placenta accreta, increta, and percreta\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/2/36902?source=see_link&amp;anchor=H9#H9\">",
"     \"Amniotic band sequence\", section on 'Differential diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     FOLLOW-UP",
"    </span>",
"    &nbsp;&mdash;&nbsp;A postoperative evaluation of the uterine cavity to assess whether a normal contour has been restored is performed; this practice is recommended by the American Association of Gynecologic Laparoscopists [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26101/abstract/10\">",
"     10",
"    </a>",
"    ]. We suggest the HSG or sonohysterogram be performed two to three months after hysteroscopic resection of intrauterine adhesions. If significant adhesive disease is identified, reoperation may be required. However, the size of the uterine cavity does not correlate well with the ability to conceive and carry a pregnancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Severe intrauterine adhesive disease is primarily caused by curettage for pregnancy complications, such as missed or incomplete abortion or postpartum hemorrhage. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinical manifestations of severe intrauterine adhesive disease include infertility, menstrual irregularities (hypomenorrhea, amenorrhea), cyclic pelvic pain, and recurrent pregnancy loss. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis is based upon visualization of the adhesions, directly by hysteroscopy, or indirectly by hysterosalpingogram or sonohysterogram. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment is by hysteroscopic lysis of the adhesions. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Lysis of adhesions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest placement of a Foley catheter in the uterine cavity immediately postoperatively to decrease reformation of adhesions (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A postoperative evaluation of the uterine cavity to assess whether a normal contour has been restored is performed. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Follow-up'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26101/abstract/1\">",
"      March CM. Intrauterine adhesions. Obstet Gynecol Clin North Am 1995; 22:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26101/abstract/2\">",
"      Schenker JG. Etiology of and therapeutic approach to synechia uteri. Eur J Obstet Gynecol Reprod Biol 1996; 65:109.",
"     </a>",
"    </li>",
"    <li>",
"     Letterie, GS. Structural abnormalities and reproductive failure: effective techniques for diagnosis and management, Blackwell Science, Massachusetts 1998.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26101/abstract/4\">",
"      Al-Inany H. Intrauterine adhesions. An update. Acta Obstet Gynecol Scand 2001; 80:986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26101/abstract/5\">",
"      Polishuk WZ, Anteby SO, Weinstein D. Puerperal endometritis and intrauterine adhesions. Int Surg 1975; 60:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26101/abstract/6\">",
"      The American Fertility Society classifications of adnexal adhesions, distal tubal occlusion, tubal occlusion secondary to tubal ligation, tubal pregnancies, m&uuml;llerian anomalies and intrauterine adhesions. Fertil Steril 1988; 49:944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26101/abstract/7\">",
"      NETTER A, MUSSET R, LAMBERT A, et al. [Tuberculous endo-uterine symphysis; an anatomo-clinical and radiologically characteristic syndrome]. Gynecol Obstet (Paris) 1955; 54:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26101/abstract/8\">",
"      ASHERMAN JG. Traumatic intra-uterine adhesions. J Obstet Gynaecol Br Emp 1950; 57:892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26101/abstract/9\">",
"      ASHERMAN JG. Amenorrhoea traumatica (atretica). J Obstet Gynaecol Br Emp 1948; 55:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26101/abstract/10\">",
"      AAGL Practice Report: Practice Guidelines for Management of Intrauterine Synechiae. J Minim Invas Gynecol 2010; 17:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26101/abstract/11\">",
"      Soares SR, Barbosa dos Reis MM, Camargos AF. Diagnostic accuracy of sonohysterography, transvaginal sonography, and hysterosalpingography in patients with uterine cavity diseases. Fertil Steril 2000; 73:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26101/abstract/12\">",
"      Roma Dalf&oacute; A, Ubeda B, Ubeda A, et al. Diagnostic value of hysterosalpingography in the detection of intrauterine abnormalities: a comparison with hysteroscopy. AJR Am J Roentgenol 2004; 183:1405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26101/abstract/13\">",
"      Shalev J, Meizner I, Bar-Hava I, et al. Predictive value of transvaginal sonography performed before routine diagnostic hysteroscopy for evaluation of infertility. Fertil Steril 2000; 73:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26101/abstract/14\">",
"      Fedele L, Bianchi S, Dorta M, Vignali M. Intrauterine adhesions: detection with transvaginal US. Radiology 1996; 199:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26101/abstract/15\">",
"      Schlaff WD, Hurst BS. Preoperative sonographic measurement of endometrial pattern predicts outcome of surgical repair in patients with severe Asherman's syndrome. Fertil Steril 1995; 63:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26101/abstract/16\">",
"      Fernandez H, Gervaise A, de Tayrac R. Operative hysteroscopy for infertility using normal saline solution and a coaxial bipolar electrode: a pilot study. Hum Reprod 2000; 15:1773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26101/abstract/17\">",
"      Levine RU, Neuwirth RS. Simultaneous laparoscopy and hysteroscopy for intrauterine adhesions. Obstet Gynecol 1973; 42:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26101/abstract/18\">",
"      Thomson AJ, Abbott JA, Kingston A, et al. Fluoroscopically guided synechiolysis for patients with Asherman's syndrome: menstrual and fertility outcomes. Fertil Steril 2007; 87:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26101/abstract/19\">",
"      Orhue AA, Aziken ME, Igbefoh JO. A comparison of two adjunctive treatments for intrauterine adhesions following lysis. Int J Gynaecol Obstet 2003; 82:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26101/abstract/20\">",
"      Pabu&ccedil;cu R, Atay V, Orhon E, et al. Hysteroscopic treatment of intrauterine adhesions is safe and effective in the restoration of normal menstruation and fertility. Fertil Steril 1997; 68:1141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26101/abstract/21\">",
"      Zikopoulos KA, Kolibianakis EM, Platteau P, et al. Live delivery rates in subfertile women with Asherman's syndrome after hysteroscopic adhesiolysis using the resectoscope or the Versapoint system. Reprod Biomed Online 2004; 8:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26101/abstract/22\">",
"      Capella-Allouc S, Morsad F, Rongi&egrave;res-Bertrand C, et al. Hysteroscopic treatment of severe Asherman's syndrome and subsequent fertility. Hum Reprod 1999; 14:1230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26101/abstract/23\">",
"      Katz Z, Ben-Arie A, Lurie S, et al. Reproductive outcome following hysteroscopic adhesiolysis in Asherman's syndrome. Int J Fertil Menopausal Stud 1996; 41:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26101/abstract/24\">",
"      Valle RF, Sciarra JJ. Intrauterine adhesions: hysteroscopic diagnosis, classification, treatment, and reproductive outcome. Am J Obstet Gynecol 1988; 158:1459.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3285 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-201.211.0.116-717FAB84F9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_31_26101=[""].join("\n");
var outline_f25_31_26101=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Lysis of adhesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Prevention of adhesion reformation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/3285\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/3285|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?11/51/12080\" title=\"diagnostic image 1\">",
"      Intrauterine adhesion hysterosc",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?22/4/22593\" title=\"diagnostic image 2\">",
"      Intrauterine adhesions",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/2/36902?source=related_link\">",
"      Amniotic band sequence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/7/8311?source=related_link\">",
"      Clinical features and diagnosis of placenta accreta, increta, and percreta",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/37/24150?source=related_link\">",
"      Hysterosalpingography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/17/9498?source=related_link\">",
"      Overview of hysteroscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/11/39097?source=related_link\">",
"      Postpartum endometritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/55/40823?source=related_link\">",
"      Saline infusion sonohysterography",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_31_26102="Peginesatide: Drug information";
var content_f25_31_26102=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Peginesatide: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?22/14/22757?source=see_link\">",
"    see \"Peginesatide: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block spa drugH1Div\" id=\"F16253119\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Special Alerts",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Peginesatide (Omontys&reg;) Injection - Product Recall",
"     </span>",
"     <span class=\"collapsible-date\">",
"      February 2013",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Affymax and Takeda Pharmaceuticals are voluntarily recalling all lots of Omontys&reg; (peginesatide) injection as a result of postmarketing reports regarding serious hypersensitivity reactions, including anaphylaxis, which can be life-threatening or fatal. The overall rate of hypersensitivity reactions reported is approximately 0.2% (approximately one-third of these reactions reported as serious, including fatalities, and occurred within 30 minutes following administration).",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       <b>",
"        Dialysis organizations should discontinue use of peginesatide.",
"       </b>",
"       Customers will be provided with instructions on how to return the product to the manufacturer for a refund. For questions, call 1-855-466-6689, 9 AM to 5 PM EST, Monday through Friday. Healthcare professionals and patients are encouraged to report adverse events or side effects related to the use of this product to the FDA's MedWatch Safety Information and Adverse Event Reporting Program.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Further information may be found at",
"       <a href=\"file://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm340895.htm\" target=\"_blank\">",
"        file://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm340895.htm",
"       </a>",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F14182839\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F14219619\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Omontys&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F13931265\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Colony Stimulating Factor;",
"     </li>",
"     <li>",
"      Erythropoiesis-Stimulating Agent (ESA);",
"     </li>",
"     <li>",
"      Growth Factor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F14186128\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Anemia associated with chronic kidney disease in patients receiving dialysis:",
"     </b>",
"     I.V., SubQ: Individualize dosing and use the lowest dose necessary to reduce the need for RBC transfusions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Patients not currently receiving an erythropoiesis-stimulating agent (ESA)",
"     </i>",
"     (initiate when hemoglobin is &lt;10 g/dL):  I.V., SubQ: Initial dose: 0.04 mg/kg once monthly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Conversion from another ESA (epoetin or darbepoetin) to peginesatide:",
"     </i>",
"     <b>",
"      Note:",
"     </b>",
"     The initial monthly peginesatide dose can be estimated based on the weekly dose of epoetin or darbepoetin at the time of substitution (see table); the same route of administration (SubQ or I.V.) of the previous ESA should be maintained after conversion to peginesatide. If previous ESA was epoetin, the first dose of peginesatide should be 1 week after the last epoetin dose. If previous ESA was darbepoetin, the first dose of peginesatide should be given in the place of darbepoetin at the next scheduled dose.",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption style=\"text-align:center;\">",
"      Conversion from Another ESA (Epoetin or Darbepoetin) to Peginesatide",
"     </caption>",
"     <col align=\"center\" width=\"130\">",
"     </col>",
"     <col align=\"center\" width=\"130\">",
"     </col>",
"     <col align=\"center\" width=\"130\">",
"     </col>",
"     <thead valign=\"middle\">",
"      <tr>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;text-align:center;\">",
"         Previous",
"        </p>",
"        <p style=\"text-indent:0em;text-align:center;\">",
"         <b>",
"          <i>",
"           Epoetin Alfa",
"          </i>",
"         </b>",
"        </p>",
"        <p style=\"text-indent:0em;text-align:center;\">",
"         Total WEEKLY Dose",
"        </p>",
"        <p style=\"text-indent:0em;text-align:center;\">",
"         (units/wk)",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;text-align:center;\">",
"         Previous",
"        </p>",
"        <p style=\"text-indent:0em;text-align:center;\">",
"         <b>",
"          <i>",
"           Darbepoetin Alfa",
"          </i>",
"         </b>",
"        </p>",
"        <p style=\"text-indent:0em;text-align:center;\">",
"         WEEKLY Dose",
"        </p>",
"        <p style=\"text-indent:0em;text-align:center;\">",
"         (mcg/wk)",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;text-align:center;\">",
"         Initial",
"        </p>",
"        <p style=\"text-indent:0em;text-align:center;\">",
"         <b>",
"          <i>",
"           Peginesatide",
"          </i>",
"         </b>",
"        </p>",
"        <p style=\"text-indent:0em;text-align:center;\">",
"         MONTHLY Dose",
"        </p>",
"        <p style=\"text-indent:0em;text-align:center;\">",
"         (mg/mo)",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tbody valign=\"middle\">",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &lt;2500",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &lt;12",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2500 to &lt;4300",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         12 to &lt;18",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         3",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         4300 to &lt;6500",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         18 to &lt;25",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         4",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         6500 to &lt;8900",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         25 to &lt;35",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         5",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         8900 to &lt;13,000",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         35 to &lt;45",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         6",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         13,000 to &lt;19,000",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         45 to &lt;60",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         8",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         19,000 to &lt;33,000",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         60 to &lt;95",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         10",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         33,000 to &lt;68,000",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         95 to &lt;175",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         15",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &ge;68,000",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &ge;175",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         20",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <i>",
"      Dosage adjustments:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     If hemoglobin does not increase by &gt;1 g/dL after 4 weeks: Increase dose by 25%; do not increase the dose more frequently than once every 4 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     If hemoglobin increases &gt;1 g/dL in the 2-week period prior to the dose or &gt;2 g/dL in 4 weeks: Reduce dose by 25% (or more) as needed to reduce rapid response",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     If hemoglobin approaches or exceeds 11 g/dL: Reduce or interrupt dose; after dose has been withheld and once the hemoglobin begins to decrease, may resume dose at ~25% below the previous dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Inadequate or lack of response over a 12-week escalation period: Further increases are unlikely to improve response and may increase risks; use the minimum effective dose that will maintain a Hgb level sufficient to avoid RBC transfusions and evaluate patient for other causes of anemia. Discontinue therapy if responsiveness does not improve.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <i>",
"      Missed doses:",
"     </i>",
"     Administer a missed dose as soon as possible and restart peginesatide at the prescribed once monthly dosing frequency.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F14186129\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F14186131\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F14186130\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F14219620\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Omontys&reg;: 10 mg/mL (1 mL, 2 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F14186183\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F14182842\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM297877.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM297877.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F14186238\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be administered as an I.V. injection or SubQ injection. The I.V. route is generally used for hemodialysis patients; medication is injected via a special access port on the dialysis tubing during the dialysis procedure. Peritoneal dialysis patients should only administer therapy via the SubQ route. For SubQ injections, may inject in either the outer area of the upper arms, the front of the middle thighs, the abdomen (excluding the 2-inch area around the navel), or the upper outer buttocks area. Do not inject in skin that is tender, red, hard, scarred, or bruised.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F13922146\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of anemia due to chronic kidney disease (CKD) in patients receiving dialysis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Peginesatide is",
"     <b>",
"      not",
"     </b>",
"     indicated for use under the following conditions:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; CKD patients not receiving dialysis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Cancer patients with anemia that is not due to CKD",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; As a substitute for RBC transfusion in patients requiring immediate correction of anemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Peginesatide has not demonstrated improved symptoms, physical functioning, or health-related quality of life.",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F14182840\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Peginesatide may be confused with pegaptanib, pegaspargase, pegfilgrastim, peginterferon, pegvisomant",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F14186220\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Hypotension (14%), hypertension (13%), procedural hypotension (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Headache (15%), fever (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Endocrine &amp; metabolic: Hyperkalemia (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Diarrhea (18%), nausea (17%), vomiting (15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Muscle spasms (15%), arthralgia (11%), back pain (11%), extremity pain (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Dyspnea (18%), cough (16%), upper respiratory tract infection (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Arteriovenous fistula site complication (16%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%: Miscellaneous: Peginesatide-specific binding antibodies (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Allergic reaction, infusion-related reactions, seizures",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F14186187\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serious hypersensitivity to peginesatide or any component of the formulation; uncontrolled hypertension",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F14186188\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Allergic reactions: Allergic reactions, including anaphylactic reactions, hypotension, bronchospasm, angioedema, and generalized pruritus, have been reported (rarely). Discontinue immediately and treat symptoms appropriately in patients who experience serious allergic/anaphylactic reactions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Lack/loss of response: Patients with a sudden loss of hemoglobin response should be evaluated for potential causes of decreased response (eg, iron deficiency, infection, bleeding, inflammation). If common causes are excluded, patient should be evaluated for the presence of peginesatide antibodies. During trials, peginesatide-specific binding antibodies were detected rarely (with a higher incidence noted in patients receiving subcutaneous compared to I.V. administration); however, no cases of pure red cell aplasia (PRCA) were observed in studies. Peginesatide is a synthetic, peptide-based erythropoiesis-stimulating agent (ESA) and cross-reactivity of the immune response against either endogenous or recombinant protein-based erythropoietin agents (eg, epoetin, darbepoetin) to peginesatide is unlikely due to the difference in amino acid sequence (Macdougall, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cancer patients: Clinical trials involving ESAs in cancer patients have shown an increased risk of death, MI, and stroke. Peginesatide is not indicated in cancer patients with anemia who do not have chronic kidney disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Chronic kidney disease patients:",
"     <b>",
"      [U.S. Boxed Warning]: An increased risk of death, serious cardiovascular events, and stroke were reported in chronic kidney disease (CKD) patients administered ESAs to target hemoglobin levels &gt;11 g/dL; use the lowest dose sufficient to reduce the need for RBC transfusions. An optimal target hemoglobin level, dose, or dosing strategy to reduce these risks have not been identified in clinical trials.",
"     </b>",
"     Hemoglobin rising &gt;1 g/dL in a 2-week period may contribute to the risk (dosage reduction recommended). CKD patients who exhibit an inadequate hemoglobin response to ESA therapy may be at a higher risk for cardiovascular events and mortality compared to other patients. Adjustments in dialysis parameters may be needed after initiation of peginesatide. Patients treated with peginesatide may require increased heparinization during dialysis to prevent clotting of the extracorporeal circuit. Therapy is not appropriate for anemia treatment in CKD patients",
"     <i>",
"      not",
"     </i>",
"     receiving dialysis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypertension/cardiovascular disease: Use with caution in patients with a history of hypertension (contraindicated in uncontrolled hypertension) or cardiovascular disease (history or active) and stroke. Blood pressure should be controlled prior to start of (and during) therapy. Monitor closely throughout treatment; reduce or withhold peginesatide if blood pressure becomes difficult to control.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Perisurgical patients: In clinical trials involving ESAs, an increased risk of death was observed in patients undergoing coronary artery bypass surgery (CABG) and an increased risk of deep vein thrombosis (DVT) was seen in those undergoing orthopedic procedures.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizures: Have been observed in clinical studies with use; use with caution in patients with a history of seizures. Monitor closely for neurologic symptoms during the first several months of therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Severe anemia or acute blood loss: Due to the delayed onset of erythropoiesis, peginesatide is not recommended for acute correction of severe anemia or as a substitute for emergency transfusion.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Factors impairing erythropoiesis: Prior to treatment, correct or exclude deficiencies of iron, vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     , and/or folate, as well as other factors which may impair erythropoiesis (inflammatory conditions, infections, bleeding).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Iron supplementation: Prior to and periodically during therapy, iron stores must be evaluated. Supplemental iron is recommended if serum ferritin &lt;100 mcg/L or serum transferrin saturation &lt;20%. Most patients with CKD will require iron supplementation.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F14276363\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F14276361\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F14186184\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F14186185\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in animal reproduction studies with maternal exposure similar to that observed with human doses.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F14186186\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322925\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Omontys Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg/mL (1 mL): $1297.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg/2 mL (2 mL): $2594.40",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F14186241\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Transferrin saturation and serum ferritin (prior to initiation and during therapy); hemoglobin (every 2 weeks after initiation and following dose adjustments until stable and sufficient to minimize need for RBC transfusion, then at least monthly following hemoglobin stability); blood pressure; seizures (following initiation for first few months, includes new-onset or change in seizure frequency or premonitory symptoms); allergic reaction; presence of antibodies (if common causes of lack or loss of response are ruled out)",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F14186229\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Peginesatide, a pegylated synthetic peptide, binds to the human erythropoietin receptor to induce erythropoiesis by stimulating the division and differentiation of committed erythroid progenitor cells; induces the release of reticulocytes from the bone marrow into the bloodstream, where they mature to erythrocytes. There is a dose response relationship with this effect. This results in an increase in reticulocyte counts followed by a rise in hemoglobin levels.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F14186231\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: I.V.: Dialysis patients: V",
"     <sub>",
"      d",
"     </sub>",
"     : 34.9 mL/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bioavailability: SubQ: ~46%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: I.V.: Healthy subjects: 25 hours, Dialysis patients: 47.9 hours; SubQ: Healthy patients: 53 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak: SubQ: ~48 hours",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Fan Q, Leuther KK, Holmes CP, et al, &ldquo;Preclinical Evaluation of Hematide, a Novel Erythropoiesis Stimulating Agent, for the Treatment of Anemia,&rdquo;",
"      <i>",
"       Exp Hematol",
"      </i>",
"      , 2006, 34(10):1303-11.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/31/26102/abstract-text/16982323/pubmed\" id=\"16982323\" target=\"_blank\">",
"        16982323",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Macdougall IC, Rossert J, Casadevall N, et al, &ldquo;A Peptide-Based Erythropoietin-Receptor Agonist for Pure Red-Cell Aplasia,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2009, 361(19):1848-55.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/31/26102/abstract-text/19890127/pubmed\" id=\"19890127\" target=\"_blank\">",
"        19890127",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Macdougall IC, Wiecek A, Tucker B, et al, &ldquo;Dose-Finding Study of Peginesatide for Anemia Correction in Chromic Kidney Disease Patients,&rdquo;",
"      <i>",
"       Clin J Am Soc Nephrol",
"      </i>",
"      , 2011, 6(11):2579-86.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/31/26102/abstract-text/21940838/pubmed\" id=\"21940838\" target=\"_blank\">",
"        21940838",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 83325 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-58.240.98.179-CCB85E928E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_31_26102=[""].join("\n");
var outline_f25_31_26102=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16253119\">",
"      Special Alerts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14182839\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14219619\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13931265\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14186128\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14186129\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14186131\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14186130\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14219620\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14186183\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14182842\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14186238\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13922146\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14182840\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14186220\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14186187\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14186188\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14276363\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14276361\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14186184\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14186185\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14186186\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322925\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14186241\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14186229\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14186231\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/83325\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/83325|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?22/14/22757?source=related_link\">",
"      Peginesatide: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_31_26103="Cutaneous bacillary angiomatosis";
var content_f25_31_26103=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F82760&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F82760&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Cutaneous lesion of bacillary angiomatosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_31_26103=[""].join("\n");
var outline_f25_31_26103=null;
var title_f25_31_26104="Contact dermatitis in children";
var content_f25_31_26104=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Contact dermatitis in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/31/26104/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/31/26104/contributors\">",
"     William L Weston, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/31/26104/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/31/26104/contributors\">",
"     Moise L Levy, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/31/26104/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/31/26104/contributors\">",
"     Rosamaria Corona, MD, DSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/31/26104/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Contact dermatitis refers to inflammation of the dermis and epidermis as a result of direct contact between a substance and the surface of the skin. In fact, almost all dermatitis is the result of skin surface injury from epicutaneous exposures. Contact dermatitis is divided into two broad categories: irritant contact dermatitis and allergic contact dermatitis. Irritants cause immediate inflammation of the skin; allergens cause an inflammatory response that is delayed by days.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     IRRITANT CONTACT DERMATITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Irritant contact dermatitis results from exposure to substances that cause physical, mechanical, or chemical irritation of the skin. Diaper dermatitis and dry skin dermatitis are two common forms of irritant contact dermatitis in children.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Diaper dermatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diaper dermatitis is the prototype for irritant contact dermatitis in children. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/33/37401?source=see_link\">",
"     \"Overview of diaper dermatitis in infants and children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Dry skin dermatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In dry skin dermatitis, also called xerosis, the surface of the skin appears dry and cracked; erythematous areas often appear within the surface cracks. Common causes of dry skin dermatitis in children include frequent soaping of the skin, and frequent wet-to-dry episodes (eg, lip-licking, thumb-sucking, and playing in water).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cells on the surface of the skin, called corneocytes, have the ability to bind three times their weight in water. Water binding involves corneocyte surface lipids, such as ceramides, and the proteins of the outer corneocyte envelope, such as involucrin and filaggrin [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26104/abstract/1\">",
"     1",
"    </a>",
"    ]. In a case-control study, loss of function mutations in the filaggrin gene were associated with susceptibility to chronic irritant contact dermatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26104/abstract/2\">",
"     2",
"    </a>",
"    ]. The bound water provides almost all of the skin surface moisture. It is unrelated to the state of internal hydration. Air humidity of 60 percent is ideal for the skin.",
"   </p>",
"   <p>",
"    Corneocyte disruption occurs when air humidity falls below 15 percent",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    corneocyte surface lipids are removed from the surface of the skin by soap or chemicals that cause the corneocytes to shrink from one another [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26104/abstract/3\">",
"     3",
"    </a>",
"    ]. Disruption of corneocytes causes release of the inflammatory cytokines, tumor necrosis factor-alpha (TNFa), and interleukin-1 (IL-1), which are stored in corneocytes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;In children with dry skin dermatitis, a history of excessive soaping of the skin, frequent water exposure, or excessive sweating may be obtained. On examination, the skin surface appears dry, cracked, and chapped with a macular erythema. Involvement may be limited to the hands in compulsive hand-washers, or to the feet in children who have excessive sweating or water exposure of the feet (juvenile plantar dermatosis) (",
"    <a class=\"graphic graphic_picture graphicRef62551 graphicRef76443 \" href=\"UTD.htm?14/32/14857\">",
"     picture 1A-B",
"    </a>",
"    ), or to the lips and perioral area (lip-licking dermatitis) (",
"    <a class=\"graphic graphic_picture graphicRef54887 \" href=\"UTD.htm?16/61/17366\">",
"     picture 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of dry skin dermatitis includes atopic dermatitis and the ichthyoses. In contrast to dry skin dermatitis, which typically affects a localized area, the entire surface of the skin may be affected in atopic dermatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26104/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Atopic dermatitis and the ichthyoses are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/40/42631?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of atopic dermatitis (eczema)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/7/7285?source=see_link\">",
"     \"Metabolic and inherited diseases affecting the skin\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Restoration of water and lipid to the skin surface and prevention of transepidermal water loss are essential to the treatment of dry skin dermatitis. This is best accomplished with application of moisturizers at least twice per day (",
"    <a class=\"graphic graphic_table graphicRef72872 \" href=\"UTD.htm?8/31/8700\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26104/abstract/4,6,7\">",
"     4,6,7",
"    </a>",
"    ]. In a randomized controlled trial, the use of moisturizing cream reduced transepidermal water loss, normalized skin corneometer values, and decreased irritant reactions [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26104/abstract/8\">",
"     8",
"    </a>",
"    ]. The use of nanoemulsions of lipids improves skin hydration, elasticity, and erythema [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26104/abstract/9\">",
"     9",
"    </a>",
"    ]. Overall, preparations that restore moisture to the skin surface also enhance delivery of steroids and other active topical medications into the skin [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26104/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, elimination of factors that may predispose to dryness such as excessive washing of the skin with soap is critical to the success of therapy. Moisturizers that are accidentally ingested cause no problem other than greasy stools.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     ALLERGIC CONTACT DERMATITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Allergic contact dermatitis (ACD) is an acquired, inflammatory reaction of the skin that requires absorption of antigen from the skin surface and recruitment of previously sensitized, antigen-specific T lymphocytes into the skin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Epidemiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence and prevalence of ACD in children are not known [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26104/abstract/5,9\">",
"     5,9",
"    </a>",
"    ]. The exact incidence and prevalence of ACD depends upon exposure to contact allergens, which varies according to geography (eg, poison ivy), and cultural practices (eg, jewelry wearing, the use of fragrances) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26104/abstract/11\">",
"     11",
"    </a>",
"    ]. It has been estimated that ACD accounts for at least 20 percent of all cases of childhood dermatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26104/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. However, this is probably an underestimate. As many as 25 percent of randomly selected asymptomatic children who undergo epicutaneous patch testing react to one or more antigens [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26104/abstract/11,12,14-16\">",
"     11,12,14-16",
"    </a>",
"    ], suggesting that the prevalence of ACD may be greater than 20 percent. The prevalence of ACD in children may be increasing [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26104/abstract/11\">",
"     11",
"    </a>",
"    ]. The North American Contact Dermatitis Group reported the same prevalence of contact dermatitis in 391 children as in 9670 adults (approximately 50 percent in a referral population) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26104/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    ACD has been reported in one-week-old infants [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26104/abstract/18,19\">",
"     18,19",
"    </a>",
"    ], and sensitization often begins as early as six months of age [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26104/abstract/16\">",
"     16",
"    </a>",
"    ]. By two years of age, many children are already sensitized to at least one common allergen (eg, nickel) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26104/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Pathogenesis of ACD",
"    </span>",
"    &nbsp;&mdash;&nbsp;An intact immune system is required for the development of ACD, which occurs in two phases: the sensitization phase and the elicitation phase [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26104/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The sensitization phase begins with initial exposure to the antigen, and may begin in infancy [",
"      <a class=\"abstract\" href=\"UTD.htm?25/31/26104/abstract/16\">",
"       16",
"      </a>",
"      ]. Contact antigens are usually low-molecular-weight substances that penetrate the outer layer of the skin and are taken up by Langerhans cells (LC). Sweating may enhance this process [",
"      <a class=\"abstract\" href=\"UTD.htm?25/31/26104/abstract/20\">",
"       20",
"      </a>",
"      ]. After processing the antigen and migrating to regional lymph nodes, LC present the antigen to T lymphocytes. These antigen-specific T lymphocytes undergo clonal expansion, creating a pool of cells with immune memory that can generate an immune response upon re-exposure to the allergen (the elicitation phase). Preliminary studies indicate that macrophages and neutrophils are also important in the pathophysiology of contact allergy [",
"      <a class=\"abstract\" href=\"UTD.htm?25/31/26104/abstract/21\">",
"       21",
"      </a>",
"      ]. Antigen-presenting cells and the cellular immune response are discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/53/25432?source=see_link\">",
"       \"Antigen presenting cells\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/58/6056?source=see_link\">",
"       \"The adaptive cellular immune response\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In the elicitation phase, the sensitized T lymphocytes proliferate and release inflammatory mediators, producing a localized dermatitis. The resulting dermatitis begins 12 to 24 hours after allergen exposure, peaks in three to five days, and may last three to four weeks if untreated [",
"      <a class=\"abstract\" href=\"UTD.htm?25/31/26104/abstract/20,22,23\">",
"       20,22,23",
"      </a>",
"      ]. The potency of the allergen determines the number of exposures necessary for this process to occur. A strong antigen, such as poison ivy, requires only one exposure, while weaker antigens require numerous exposures over weeks to years. Once sensitization occurs, however, it is thought to be long-lived [",
"      <a class=\"abstract\" href=\"UTD.htm?25/31/26104/abstract/9,20,22,23\">",
"       9,20,22,23",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Allergens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Contact allergens are found in both the natural and man-made environment (",
"    <a class=\"graphic graphic_table graphicRef58364 \" href=\"UTD.htm?29/13/29916\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26104/abstract/24\">",
"     24",
"    </a>",
"    ]. The most common contact allergen is urushiol, a pentadecylcatechol found in plants of the Toxicodendron species, such as poison ivy, poison oak, and poison sumac (",
"    <a class=\"graphic graphic_figure graphicRef72155 \" href=\"UTD.htm?42/4/43074\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef81397 graphicRef54814 graphicRef81173 \" href=\"UTD.htm?38/1/38938\">",
"     picture 3A-C",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/44/20168?source=see_link\">",
"     \"Poison ivy (Toxicodendron) dermatitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other common childhood contact allergens include nickel,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/57/14229?source=see_link\">",
"     neomycin",
"    </a>",
"    , chromates (tanning agents), thimerosal, Balsam of Peru (a fragrance), formaldehyde and related preservatives, colophony (rosin from wood), wool alcohol (lanolin), and several others [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26104/abstract/11,12,14-16,24-30\">",
"     11,12,14-16,24-30",
"    </a>",
"    ]. The active ingredients of sunscreens, while uncommon causes of childhood ACD, are on the increase [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26104/abstract/28\">",
"     28",
"    </a>",
"    ]. Cobalt and gold were among the top 10 allergens causing ACD in children tested by the North American Contact Dermatitis Group [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26104/abstract/17\">",
"     17",
"    </a>",
"    ]. Agents that were once thought to cause contact allergy but have been excluded on the basis of patch testing include detergents, diapers, antistatic laundry sheets, sweaty socks, and EMLA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Clinical findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;ACD presents as pruritic dermatitis localized to the site of allergen contact with the skin. The configuration and location of the dermatitis often is a clue to the offending allergen (",
"    <a class=\"graphic graphic_table graphicRef58364 \" href=\"UTD.htm?29/13/29916\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef81478 \" href=\"UTD.htm?8/53/9055\">",
"     picture 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef70989 \" href=\"UTD.htm?32/27/33203\">",
"     picture 5",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26104/abstract/29\">",
"     29",
"    </a>",
"    ]. Regional lymph nodes may be enlarged but are not tender [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26104/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    ACD may be acute, subacute, or chronic:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute ACD to potent allergens (eg, poison ivy, poison oak, poison sumac, nickel) is characterized by erythema and edema with vesicles or bullae that often rupture, leaving a crust.",
"     </li>",
"     <li>",
"      Subacute and chronic dermatitis, which are more common, are characterized by lichenification, erythema, and scaling, and are produced by less potent antigens.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Autoeczematization",
"    </span>",
"    &nbsp;&mdash;&nbsp;A more generalized dermatitis, termed autoeczematization, may develop distal to the original site of contact one or more weeks after the appearance of the initial localized dermatitis. This secondary dermatitis is also called autosensitization dermatitis or an \"id\" reaction. Autoeczematization is particularly common among children with nickel dermatitis who have subacute dermatitis at the initial site for several weeks before appearance of a more widespread dermatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26104/abstract/29\">",
"     29",
"    </a>",
"    ]. Autoeczematization is treated in the same manner as widespread disease and usually responds promptly. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Treatment of ACD'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical morphology of ACD is identical to other forms of dermatitis (eg, irritant dermatitis and atopic dermatitis). Other conditions that may be considered, depending upon the appearance of ACD, include [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26104/abstract/20\">",
"     20",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cellulitis, if ACD is associated with erythema and edema. Fever and leukocytosis, common in cellulitis, are not features of ACD. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/33/12825?source=see_link\">",
"       \"Cellulitis and erysipelas\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Herpes simplex virus, herpes zoster, impetigo (if blistering lesions are present). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/20/40265?source=see_link\">",
"       \"Clinical manifestations and diagnosis of herpes simplex virus type 1 infection\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/8/23688?source=see_link\">",
"       \"Epidemiology and pathogenesis of varicella-zoster virus infection: Herpes zoster\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21846?source=see_link\">",
"       \"Impetigo\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Fixed drug eruption, which typically recurs in the same location. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/17/41241?source=see_link&amp;anchor=H11#H11\">",
"       \"Drug eruptions\", section on 'Fixed drug eruption'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The history of allergen exposure and the pattern of the eruption are important factors in making the correct diagnosis. Patterns of dermatitis that are suggestive of ACD include persistent, localized dermatitis that has not responded as expected to therapy, and dermatitis in an unusual pattern or distribution (",
"    <a class=\"graphic graphic_table graphicRef58364 \" href=\"UTD.htm?29/13/29916\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef81478 \" href=\"UTD.htm?8/53/9055\">",
"     picture 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef70989 \" href=\"UTD.htm?32/27/33203\">",
"     picture 5",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26104/abstract/29\">",
"     29",
"    </a>",
"    ]. In contrast to ACD, which often has an unusual pattern of distribution, atopic dermatitis is typically symmetric. ACD also should be considered in any child who has a persistent dermatitis regardless of the pattern [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26104/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Patch testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the offending allergen may be identified through history, epicutaneous \"patch\" testing may be necessary to identify specific antigens or, in some cases, to make the diagnosis of ACD [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26104/abstract/24,26-32\">",
"     24,26-32",
"    </a>",
"    ]. Identifying the offending allergen is important since allergen avoidance is the key to preventing recurrence. Epicutaneous patch testing evaluates the T lymphocyte response of delayed hypersensitivity. This is in contrast to prick testing or intradermal testing, which assess antibody-mediated immediate hypersensitivity [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26104/abstract/33\">",
"     33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32633?source=see_link\">",
"     \"Overview of skin testing for allergic disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Epicutaneous patch testing involves placement of suspected and standard allergens on the skin surface, and examination after 48 hours for signs of ACD (",
"    <a class=\"graphic graphic_picture graphicRef74380 \" href=\"UTD.htm?21/5/21599\">",
"     picture 6",
"    </a>",
"    ). Reevaluation is recommended after four to five days to detect reaction to weaker antigens and to permit irritant reactions to clear [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26104/abstract/20\">",
"     20",
"    </a>",
"    ]. Children should avoid bathing and strenuous activity while the patches are in place.",
"   </p>",
"   <p>",
"    Because of the potential pitfalls in interpretation of patch tests, epicutaneous patch testing should only be performed by clinicians who are experienced in the procedure and interpretation of the test, and knowledgeable about the relevance of the antigens [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26104/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. In a retrospective case series, 80 percent of positive patch test reactions in children were relevant (with relevance determined by the presence of the allergen in the child's environment",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    improvement on allergen avoidance or exacerbation upon re-challenge) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26104/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Treatment of ACD",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of ACD involves two main principles:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The dermatitis must be treated for at least 14 to 21 days.",
"     </li>",
"     <li>",
"      The allergen must be identified and avoided in order to prevent recurrence.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Corticosteroids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute ACD is best controlled with corticosteroids, and they remain the mainstay of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26104/abstract/35-37\">",
"     35-37",
"    </a>",
"    ]. Through various mechanisms, corticosteroids decrease the production of cytokines and halt lymphocyte proliferation, limiting the inflammatory response to contact allergens [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26104/abstract/36\">",
"     36",
"    </a>",
"    ]. In two small trials, the application of topical corticosteroids resulted in decreased transepidermal water loss, clinical improvement, and suppression of allergic reaction compared to the application of placebo in patients with ACD [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26104/abstract/37,38\">",
"     37,38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When the dermatitis involves greater than 10 percent of the skin surface, systemic steroids are indicated. A single morning dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (1 to 2",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    for 7 to 10 days, followed by a taper over the next 7 to 10 days, is usually sufficient.",
"   </p>",
"   <p>",
"    Localized eruptions may be treated with corticosteroid ointments (not creams) of moderate potency applied two times daily for two to three weeks. Topical corticosteroids are classified according to strength, with group I corticosteroids being the strongest, and group VII the least strong (",
"    <a class=\"graphic graphic_table graphicRef62402 \" href=\"UTD.htm?38/56/39809\">",
"     table 3",
"    </a>",
"    ). Examples of moderate potency topical corticosteroids include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/22/36192?source=see_link\">",
"     fluocinolone",
"    </a>",
"    acetonide 0.025 percent (group IV),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/38/39520?source=see_link\">",
"     triamcinolone",
"    </a>",
"    acetonide 0.1 percent (group IV), and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/15/36080?source=see_link\">",
"     mometasone",
"    </a>",
"    furoate 0.1 percent (group III). As with systemic therapy, the topical therapy must be continued for two to three weeks, since stopping the therapy too quickly may cause rebound dermatitis.",
"   </p>",
"   <p>",
"    Subacute and chronic ACD is often the result of repeated exposures to modest or weak contact allergens, making treatment challenging. Systemic corticosteroids are effective at suppressing chronic dermatitis, but their use should be avoided in this condition since their potential side effects outweigh the benefits of the long course of therapy likely to be required [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26104/abstract/39\">",
"     39",
"    </a>",
"    ]. Depending upon the part of the body affected, low or midpotency topical corticosteroids (groups IV to VII) applied twice daily are a more reasonable alternative (",
"    <a class=\"graphic graphic_table graphicRef62402 \" href=\"UTD.htm?38/56/39809\">",
"     table 3",
"    </a>",
"    ). Appropriate long-term use of these medications does not cause hypothalamic-pituitary-adrenal suppression in infants and children [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26104/abstract/39\">",
"     39",
"    </a>",
"    ], although localized side effects, such as atrophy, are possible. Second-line therapy for subacute and chronic ACD may include immunosuppressant agents as described below. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=see_link\">",
"     \"Major side effects of systemic glucocorticoids\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Contact allergy to topical corticosteroids is a possible complication of therapy and, if suspected, may be evaluated with patch testing to identify the culprit preparation, as well as other corticosteroids that the patient can tolerate [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26104/abstract/40\">",
"     40",
"    </a>",
"    ]. The classification of topical corticosteroids in cross-reacting groups is also useful in the choice of the preparation the patient may tolerate (",
"    <a class=\"graphic graphic_figure graphicRef63402 \" href=\"UTD.htm?10/52/11075\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Side effects of topical corticosteroid therapy are reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/6/27752?source=see_link&amp;anchor=H16#H16\">",
"     \"General principles of dermatologic therapy and topical corticosteroid use\", section on 'Side effects'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Calcineurin inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two macrolide immunosuppressants,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/41/29332?source=see_link\">",
"     pimecrolimus",
"    </a>",
"    , have emerged as potential alternatives to corticosteroids in the treatment of subacute and chronic ACD [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26104/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. However, these agents are not as effective in treating ACD as midpotency corticosteroid ointments (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/38/39520?source=see_link\">",
"     triamcinolone",
"    </a>",
"    acetonide 0.1 percent or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/22/36192?source=see_link\">",
"     fluocinolone",
"    </a>",
"    acetonide 0.025 percent).",
"   </p>",
"   <p>",
"    In addition, in March 2005, the FDA issued an advisory about the possible link between topical use of calcineurin inhibitors and cancer in children and adults [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26104/abstract/43\">",
"     43",
"    </a>",
"    ]. No definite causal relationship has been established, and none of the type of lymphomas that might be expected from systemic immunosuppression related to these drugs has occurred. Further studies are underway. In the meantime, the FDA has not called for a labeling change, but advises that these agents should be used only as labeled: as second-line agents for short-term and intermittent treatment of atopic dermatitis. They should not be used in children younger than two years of age, nor in immunocompromised individuals.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"       Tacrolimus",
"      </a>",
"      , formerly FK506, is used systemically to prevent organ rejection after transplantation. It inhibits calcineurin, thereby halting the transcription of IL-2 and decreasing the responsiveness of T lymphocytes to antigenic stimuli [",
"      <a class=\"abstract\" href=\"UTD.htm?25/31/26104/abstract/41\">",
"       41",
"      </a>",
"      ]. A topical ointment in two concentrations (Protopic 0.03 percent and 0.1 percent) is approved for the treatment of atopic dermatitis, but only the 0.03 percent version is indicated for use in children aged 2 to 15 years.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/41/29332?source=see_link\">",
"       Pimecrolimus",
"      </a>",
"      , an ascomycin analog, down-regulates the production of various cytokines that are released as a result of antigen-specific stimulation of immune-memory T cells [",
"      <a class=\"abstract\" href=\"UTD.htm?25/31/26104/abstract/43\">",
"       43",
"      </a>",
"      ]. A 1 percent cream (Elidel) is approved for the treatment of mild to moderate atopic dermatitis in children two years and older [",
"      <a class=\"abstract\" href=\"UTD.htm?25/31/26104/abstract/44\">",
"       44",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Other therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to topical corticosteroids, other treatments may be beneficial in alleviating associated symptoms, such as burning or pruritus.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sedating antihistamines, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/2/33824?source=see_link\">",
"       diphenhydramine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/24/391?source=see_link\">",
"       hydroxyzine",
"      </a>",
"      , decrease itching and allow the patient to sleep through the night. As an alternative to standard dosing, we have found a single dose of hydroxyzine 1 to 2",
"      <span class=\"nowrap\">",
"       mg/kg,",
"      </span>",
"      given 30 minutes to 1 hour before bedtime, to be effective in this regard.",
"     </li>",
"     <li>",
"      Wet dressings are also soothing and help relieve itching, reduce redness, debride crusts, and limit access to the skin. Dampened cotton garments are worn over the affected area and covered with a dry garment. The patient may use these dressings overnight or change them every eight hours during the day. The author prefers wet dressings to topical agents such as calamine or Aveeno baths because wet dressings limit access to the skin and are more soothing, hydrating, and antipruritic.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Allergen avoidance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Identifying the offending allergen is important, since allergen avoidance is the key to preventing recurrence. Although the offending allergen may be identified through history, epicutaneous \"patch\" testing may be necessary to identify specific antigens [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26104/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Patch testing'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Epicutaneous patch testing should be performed by clinicians experienced with the procedures and interpretation of the results [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26104/abstract/34\">",
"     34",
"    </a>",
"    ]. Once the allergen is known, the patient should be given educational information regarding potential sources and avoidance of the antigen.",
"   </p>",
"   <p>",
"    Complete avoidance is possible in many circumstances once the source of the allergen is known. Avoidance may involve placing a barrier between the allergen and the skin. Examples include wearing long pants when out in the woods to prevent rhus dermatitis and using a cloth patch or nail enamel to cover the exposed portions of metal snaps or fasteners in a child allergic to nickel.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?42/49/43793?source=see_link\">",
"       \"Patient information: Diaper rash (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?3/3/3122?source=see_link\">",
"       \"Patient information: Poison ivy (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?6/30/6626?source=see_link\">",
"       \"Patient information: Eczema (atopic dermatitis) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?31/38/32354?source=see_link\">",
"       \"Patient information: Contact dermatitis (including latex dermatitis) (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?43/41/44690?source=see_link\">",
"       \"Patient information: Diaper rash in infants and children (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?5/59/6068?source=see_link\">",
"       \"Patient information: Poison ivy (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?15/23/15730?source=see_link\">",
"       \"Patient information: Atopic dermatitis (eczema) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Irritant dermatitis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A diagnosis of irritant contact dermatitis should be considered in children who have localized macular erythematous rashes in which the skin is dry, cracked, and chapped. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Dry skin dermatitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend the use of moisturizers (",
"      <a class=\"graphic graphic_table graphicRef72872 \" href=\"UTD.htm?8/31/8700\">",
"       table 1",
"      </a>",
"      ) for the treatment of dry skin dermatitis (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Moisturizers should be applied at least twice per day. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Avoidance of the irritant (eg, frequent bathing, lip licking, soaps, etc.) is essential in the treatment of dry skin dermatitis. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Allergic dermatitis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Allergic contact dermatitis (ACD) should be considered in children who have localized pruritic dermatitis 12 to 24 hours after exposure to a contact allergen to which they have been sensitized. The configuration and location of the dermatitis often is a clue to the offending allergen. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Clinical findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Epicutaneous \"patch\" testing may be necessary to make the diagnosis of ACD or to identify specific antigens. Patch testing should be performed by clinicians with experience in its performance and interpretation. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Patch testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend corticosteroids as the first-line therapy for ACD (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Corticosteroid therapy should be provided for a minimum of 14 to 21 days. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Corticosteroids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Systemic corticosteroids are indicated in the treatment of acute ACD that involves greater than 10 percent of the skin surface. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Corticosteroids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Twice-daily topical therapy with a midpotency corticosteroid ointment (",
"      <a class=\"graphic graphic_table graphicRef62402 \" href=\"UTD.htm?38/56/39809\">",
"       table 3",
"      </a>",
"      ) is indicated for localized acute ACD and subacute or chronic ACD. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Corticosteroids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest not using systemic corticosteroids in the treatment of subacute or chronic ACD (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Corticosteroids'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=see_link\">",
"       \"Major side effects of systemic glucocorticoids\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Calcineurin inhibitors may be used as a second-line therapy for the treatment of corticosteroid-resistant subacute or chronic ACD. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Calcineurin inhibitors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Sedating antihistamines, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/2/33824?source=see_link\">",
"       diphenhydramine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/24/391?source=see_link\">",
"       hydroxyzine",
"      </a>",
"      , and wet dressings are adjuncts to therapy for ACD. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Other therapies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Avoidance of the allergen is essential in the treatment of ACD. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Allergen avoidance'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26104/abstract/1\">",
"      Abe T. Studies on skin surface barrier functions. Transepidermal water loss and skin surface lipids during childhood. Chem Pharm Bull (Tokyo) 1978; 26:1659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26104/abstract/2\">",
"      de Jongh CM, Khrenova L, Verberk MM, et al. Loss-of-function polymorphisms in the filaggrin gene are associated with an increased susceptibility to chronic irritant contact dermatitis: a case-control study. Br J Dermatol 2008; 159:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26104/abstract/3\">",
"      Seidenari S, Giusti G. Objective assessment of the skin of children affected by atopic dermatitis: a study of pH, capacitance and TEWL in eczematous and clinically uninvolved skin. Acta Derm Venereol 1995; 75:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26104/abstract/4\">",
"      Chamlin SL, Kao J, Frieden IJ, et al. Ceramide-dominant barrier repair lipids alleviate childhood atopic dermatitis: changes in barrier function provide a sensitive indicator of disease activity. J Am Acad Dermatol 2002; 47:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26104/abstract/5\">",
"      Williams HC, Burney PG, Strachan D, Hay RJ. The U.K. Working Party's Diagnostic Criteria for Atopic Dermatitis. II. Observer variation of clinical diagnosis and signs of atopic dermatitis. Br J Dermatol 1994; 131:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26104/abstract/6\">",
"      Lynde CW. Moisturizers: what they are and how they work. Skin Therapy Lett 2001; 6:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26104/abstract/7\">",
"      Lod&eacute;n M. Role of topical emollients and moisturizers in the treatment of dry skin barrier disorders. Am J Clin Dermatol 2003; 4:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26104/abstract/8\">",
"      Lod&eacute;n M. Barrier recovery and influence of irritant stimuli in skin treated with a moisturizing cream. Contact Dermatitis 1997; 36:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26104/abstract/9\">",
"      Yilmaz E, Borchert HH. Effect of lipid-containing, positively charged nanoemulsions on skin hydration, elasticity and erythema--an in vivo study. Int J Pharm 2006; 307:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26104/abstract/10\">",
"      Orchard D, Weston WL. The importance of vehicle in pediatric topical therapy. Pediatr Ann 2001; 30:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26104/abstract/11\">",
"      Militello G, Jacob SE, Crawford GH. Allergic contact dermatitis in children. Curr Opin Pediatr 2006; 18:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26104/abstract/12\">",
"      Weston WL, Weston JA, Kinoshita J, et al. Prevalence of positive epicutaneous tests among infants, children, and adolescents. Pediatrics 1986; 78:1070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26104/abstract/13\">",
"      Jacob SE, Steele T, Brod B, Crawford GH. Dispelling the myths behind pediatric patch testing-experience from our tertiary care patch testing centers. Pediatr Dermatol 2008; 25:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26104/abstract/14\">",
"      Mortz CG, Lauritsen JM, Bindslev-Jensen C, Andersen KE. Prevalence of atopic dermatitis, asthma, allergic rhinitis, and hand and contact dermatitis in adolescents. The Odense Adolescence Cohort Study on Atopic Diseases and Dermatitis. Br J Dermatol 2001; 144:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26104/abstract/15\">",
"      Barros MA, Baptista A, Correia TM, Azevedo F. Patch testing in children: a study of 562 schoolchildren. Contact Dermatitis 1991; 25:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26104/abstract/16\">",
"      Silverberg NB, Licht J, Friedler S, et al. Nickel contact hypersensitivity in children. Pediatr Dermatol 2002; 19:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26104/abstract/17\">",
"      Zug KA, McGinley-Smith D, Warshaw EM, et al. Contact allergy in children referred for patch testing: North American Contact Dermatitis Group data, 2001-2004. Arch Dermatol 2008; 144:1329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26104/abstract/18\">",
"      Bruckner AL, Weston WL, Morelli JG. Does sensitization to contact allergens begin in infancy? Pediatrics 2000; 105:e3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26104/abstract/19\">",
"      Seidenari S, Manzini BM, Motolese A. Contact sensitization in infants: report of 3 cases. Contact Dermatitis 1992; 27:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26104/abstract/20\">",
"      Weston WL, Bruckner A. Allergic contact dermatitis. Pediatr Clin North Am 2000; 47:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26104/abstract/21\">",
"      Tuckermann JP, Kleiman A, Moriggl R, et al. Macrophages and neutrophils are the targets for immune suppression by glucocorticoids in contact allergy. J Clin Invest 2007; 117:1381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26104/abstract/22\">",
"      Bruckner AL, Weston WL. Beyond poison ivy: understanding allergic contact dermatitis in children. Pediatr Ann 2001; 30:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26104/abstract/23\">",
"      Hogan PA, Weston WL. Allergic contact dermatitis in children. Pediatr Rev 1993; 14:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26104/abstract/24\">",
"      Brasch J, Geier J. Patch test results in schoolchildren. Results from the Information Network of Departments of Dermatology (IVDK) and the German Contact Dermatitis Research Group (DKG). Contact Dermatitis 1997; 37:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26104/abstract/25\">",
"      Clayton TH, Wilkinson SM, Rawcliffe C, et al. Allergic contact dermatitis in children: should pattern of dermatitis determine referral? A retrospective study of 500 children tested between 1995 and 2004 in one U.K. centre. Br J Dermatol 2006; 154:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26104/abstract/26\">",
"      W&ouml;hrl S, Hemmer W, Focke M, et al. Patch testing in children, adults, and the elderly: influence of age and sex on sensitization patterns. Pediatr Dermatol 2003; 20:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26104/abstract/27\">",
"      Seidenari S, Giusti F, Pepe P, Mantovani L. Contact sensitization in 1094 children undergoing patch testing over a 7-year period. Pediatr Dermatol 2005; 22:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26104/abstract/28\">",
"      Bryden AM, Moseley H, Ibbotson SH, et al. Photopatch testing of 1155 patients: results of the U.K. multicentre photopatch study group. Br J Dermatol 2006; 155:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26104/abstract/29\">",
"      Sharma V, Beyer DJ, Paruthi S, Nopper AJ. Prominent pruritic periumbilical papules: allergic contact dermatitis to nickel. Pediatr Dermatol 2002; 19:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26104/abstract/30\">",
"      Jacob SE, Burk CJ, Connelly EA. Patch testing: another steroid-sparing agent to consider in children. Pediatr Dermatol 2008; 25:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26104/abstract/31\">",
"      Bruckner AL, Weston WL. Allergic contact dermatitis in children: a practical approach to management. Skin Therapy Lett 2002; 7:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26104/abstract/32\">",
"      Jacob SE, Brod B, Crawford GH. Clinically relevant patch test reactions in children--a United States based study. Pediatr Dermatol 2008; 25:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26104/abstract/33\">",
"      Stables GI, Forsyth A, Lever RS. Patch testing in children. Contact Dermatitis 1996; 34:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26104/abstract/34\">",
"      Sherertz EF. Patch testing children. Pediatr Dermatol 1998; 15:68.",
"     </a>",
"    </li>",
"    <li>",
"     Wolverton SE. Systemic corticosteroids. In: Comprehensive Dermatologic Drug Therapy, Wolverton SE (Ed), WB Saunders, Philadelphia 2001. p.109.",
"    </li>",
"    <li>",
"     Weston WL, Lane AT, Morelli JG. Color Textbook of Pediatric Dermatology, 4th ed, Mosby-Elsevier, London 2007.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26104/abstract/37\">",
"      Hachem JP, De Paepe K, Vanp&eacute;e E, et al. Efficacy of topical corticosteroids in nickel-induced contact allergy. Clin Exp Dermatol 2002; 27:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26104/abstract/38\">",
"      Green C. The effect of topically applied corticosteroid on irritant and allergic patch test reactions. Contact Dermatitis 1996; 35:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26104/abstract/39\">",
"      Ellison JA, Patel L, Ray DW, et al. Hypothalamic-pituitary-adrenal function and glucocorticoid sensitivity in atopic dermatitis. Pediatrics 2000; 105:794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26104/abstract/40\">",
"      Davis MD, el-Azhary RA, Farmer SA. Results of patch testing to a corticosteroid series: a retrospective review of 1188 patients during 6 years at Mayo Clinic. J Am Acad Dermatol 2007; 56:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26104/abstract/41\">",
"      Meingassner JG, St&uuml;tz A. Immunosuppressive macrolides of the type FK 506: a novel class of topical agents for treatment of skin diseases? J Invest Dermatol 1992; 98:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26104/abstract/42\">",
"      Pacor ML, Di Lorenzo G, Martinelli N, et al. Tacrolimus ointment in nickel sulphate-induced steroid-resistant allergic contact dermatitis. Allergy Asthma Proc 2006; 27:527.",
"     </a>",
"    </li>",
"    <li>",
"     FDA Public Health Advisory. Elidel (pimecrolimus) Cream and Protopic (tacrolimus) Ointment, March 2005. www.fda.gov/cder/drug/advisory/elidel_protopic.htm (Accessed on March 29, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26104/abstract/44\">",
"      Paul C, Cork M, Rossi AB, et al. Safety and tolerability of 1% pimecrolimus cream among infants: experience with 1133 patients treated for up to 2 years. Pediatrics 2006; 117:e118.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1731 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-CCFD8525CC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_31_26104=[""].join("\n");
var outline_f25_31_26104=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      IRRITANT CONTACT DERMATITIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Diaper dermatitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Dry skin dermatitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Clinical features",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      ALLERGIC CONTACT DERMATITIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Epidemiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Pathogenesis of ACD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Allergens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Clinical findings",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Autoeczematization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Patch testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Treatment of ACD",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Corticosteroids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Calcineurin inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Other therapies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Allergen avoidance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Irritant dermatitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Allergic dermatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/1731\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/1731|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/4/43074\" title=\"figure 1\">",
"      Identification poison ivy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?10/52/11075\" title=\"figure 2\">",
"      Cross-reactivity of topical corticosteroids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/1731|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?36/58/37796\" title=\"picture 1A\">",
"      Juvenile plantar dermatosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/21/23892\" title=\"picture 1B\">",
"      Juvenile plantar dermatosis 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?16/61/17366\" title=\"picture 2\">",
"      Lip-licking dermatitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/1/22549\" title=\"picture 3A\">",
"      Poison ivy 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?38/1/38931\" title=\"picture 3B\">",
"      Poison ivy fruit",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?7/41/7832\" title=\"picture 3C\">",
"      Poison oak",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?8/53/9055\" title=\"picture 4\">",
"      Chromate allergy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?32/27/33203\" title=\"picture 5\">",
"      Nickel allergy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?21/5/21599\" title=\"picture 6\">",
"      Positive patch test",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/1731|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/31/8700\" title=\"table 1\">",
"      Types of moisturizers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/13/29916\" title=\"table 2\">",
"      Contact allergens children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/56/39809\" title=\"table 3\">",
"      Topical corticosteroids",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/53/25432?source=related_link\">",
"      Antigen presenting cells",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/33/12825?source=related_link\">",
"      Cellulitis and erysipelas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/20/40265?source=related_link\">",
"      Clinical manifestations and diagnosis of herpes simplex virus type 1 infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/17/41241?source=related_link\">",
"      Drug eruptions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/8/23688?source=related_link\">",
"      Epidemiology and pathogenesis of varicella-zoster virus infection: Herpes zoster",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/40/42631?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of atopic dermatitis (eczema)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/6/27752?source=related_link\">",
"      General principles of dermatologic therapy and topical corticosteroid use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21846?source=related_link\">",
"      Impetigo",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/7/7285?source=related_link\">",
"      Metabolic and inherited diseases affecting the skin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/33/37401?source=related_link\">",
"      Overview of diaper dermatitis in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32633?source=related_link\">",
"      Overview of skin testing for allergic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?15/23/15730?source=related_link\">",
"      Patient information: Atopic dermatitis (eczema) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?31/38/32354?source=related_link\">",
"      Patient information: Contact dermatitis (including latex dermatitis) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?42/49/43793?source=related_link\">",
"      Patient information: Diaper rash (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?43/41/44690?source=related_link\">",
"      Patient information: Diaper rash in infants and children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/30/6626?source=related_link\">",
"      Patient information: Eczema (atopic dermatitis) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?5/59/6068?source=related_link\">",
"      Patient information: Poison ivy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?3/3/3122?source=related_link\">",
"      Patient information: Poison ivy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/44/20168?source=related_link\">",
"      Poison ivy (Toxicodendron) dermatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/58/6056?source=related_link\">",
"      The adaptive cellular immune response",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_31_26105="Retained surgical sponge (gossypiboma) and other retained surgical foreign bodies: Prevention and management";
var content_f25_31_26105=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Retained surgical sponge (gossypiboma) and other retained surgical foreign bodies: Prevention and management",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/31/26105/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/31/26105/contributors\">",
"     Annesley W Copeland, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/31/26105/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/31/26105/contributors\">",
"     Hilary Sanfey, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/31/26105/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/31/26105/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/31/26105/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H251480748\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Retained surgical foreign objects are any surgical sponge, instrument, tool, or device that is unintentionally left in the patient at the completion of the operation after closure of the wound. Surgical sponges are more commonly retained compared with other objects used in surgery.",
"   </p>",
"   <p>",
"    Retained surgical foreign bodies are rare medical errors that have the potential to cause significant harm to the patient and carry profound professional and medico-legal consequences to physicians and hospitals. Risk factors for this problem are well described and include both patient care processes and working environment issues.",
"   </p>",
"   <p>",
"    Although there are no known measures to completely eliminate the risk, preventive strategies aim primarily to increase awareness. Some newer technologies are available and show promising results but have not been widely adopted. The definition, types, incidence, risk factors, complications and prevention strategies will be reviewed here.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H251480801\">",
"    <span class=\"h1\">",
"     RETAINED OBJECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common retained foreign body is a woven cotton surgical sponge, which includes both laparotomy pads and smaller sponges (eg, Ray-tec&reg;) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26105/abstract/1\">",
"     1",
"    </a>",
"    ]. Sponges are easily retained because of their ubiquitous use, relatively small size, and because, when soaked in blood, sponges conform to and can be difficult to distinguish from surrounding tissues.",
"   </p>",
"   <p>",
"    The problem of retained surgical sponge is known as gossypiboma, and also as &ldquo;textiloma&rdquo;, &ldquo;gauzoma&rdquo;, or &ldquo;muslinoma&rdquo;. The word gossypiboma may have been formed from the Latin &ldquo;gossypium&rdquo; meaning &ldquo;cotton&rdquo; and Swahili &ldquo;boma&rdquo; meaning &ldquo;place of concealment&rdquo; [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26105/abstract/2\">",
"     2",
"    </a>",
"    ]. Others indicate &ldquo;&ndash;oma&rdquo; was added to gossypi to indicate a growth, as in the example textiloma [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26105/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Surgical instruments, needles, and other items can also be inadvertently left behind in surgical fields [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26105/abstract/4\">",
"     4",
"    </a>",
"    ]. Clamps and retractors are the most common types of a retained instrument, but items such as electrodes, electrocautery scratch pads, drains, and pieces of suction tubing have been described. The potential risk of leaving other materials associated with negative pressure wound therapy dressings in complex open wounds has been recognized [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26105/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/41/26264?source=see_link&amp;anchor=H2#H2\">",
"     \"Negative pressure wound therapy\", section on 'Device and placement'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H251480808\">",
"    <span class=\"h1\">",
"     INCIDENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is estimated that retained surgical foreign bodies occur in 1 in every 5500 to 18,760 inpatient operations [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26105/abstract/7,8\">",
"     7,8",
"    </a>",
"    ], but may be as high as 1 of every 1000 to 1500 abdominal cavity operations [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26105/abstract/9\">",
"     9",
"    </a>",
"    ], and even more common during emergency surgery. In a retrospective review from a Level I trauma center, three cases of retained foreign bodies (all sponges) occurred in 2075 trauma laparotomies over an eight-year period, for an incidence of approximately 1 in 700 [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26105/abstract/10\">",
"     10",
"    </a>",
"    ]. Intuitively, laparoscopic, endoscopic, and percutaneous procedures are less likely to lead to a retained sponge or instrument. &nbsp;",
"   </p>",
"   <p>",
"    The incidence of retained sponge depends, in part, upon the anatomic location of the procedure. Retained sponges in adults occur most commonly in the abdomen (56 percent), pelvis (18 percent), and thorax (11 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26105/abstract/11\">",
"     11",
"    </a>",
"    ]. However, it has been described with spinal [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26105/abstract/12\">",
"     12",
"    </a>",
"    ], extremity [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26105/abstract/13\">",
"     13",
"    </a>",
"    ], intracranial [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26105/abstract/14\">",
"     14",
"    </a>",
"    ], vascular [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26105/abstract/15\">",
"     15",
"    </a>",
"    ], breast [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26105/abstract/16\">",
"     16",
"    </a>",
"    ], pediatric [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26105/abstract/17\">",
"     17",
"    </a>",
"    ], and even facial plastic surgery procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26105/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H251481323\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple studies have attempted to identify factors associated with retained surgical foreign bodies [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26105/abstract/7,8,19\">",
"     7,8,19",
"    </a>",
"    ]. The results have not been consistent. Factors that have been implicated as important include emergency surgical procedures, an unexpected change in the course of the surgical procedure, patient obesity, damage control surgery, the involvement of two or more surgical teams, procedures involving one or more open body cavities, prolonged surgical procedures, the use of an unusually large number of instruments and the absence of the attending surgeon at final closure.",
"   </p>",
"   <p>",
"    In a retrospective study that used malpractice insurance files and identified 61 retained surgical foreign bodies, a multivariate analysis identified three factors that were significantly associated with an increased risk: an emergency procedure (risk ratio [RR] 8.8, 95% CI 2.4-31.9), unplanned change in the procedure performed (RR 4.1, 95% CI 1.4-12.4), and increased body mass index (RR per one-unit increment 1.1, 95% CI 1.0-1.2) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26105/abstract/7\">",
"     7",
"    </a>",
"    ]. Other factors that were thought to be important such as the estimated volume of blood lost, changes in nursing personnel, and duration of the case, were not associated with an increased risk.",
"   </p>",
"   <p>",
"    A risk factor that may have been overlooked in the above studies is the importance of communication. In a retrospective study of 34 retained foreign objects, the single most important factor was felt to be a breakdown in communication [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26105/abstract/8\">",
"     8",
"    </a>",
"    ]. The two most common communication problems were failure of the surgeon to convey placement of the item within a body cavity to other team members, and failure by the person performing the action to remember that action before closing. In contrast to the data derived from malpractice insurance files, an emergency procedure was not identified as a risk factor in this study.",
"   </p>",
"   <p>",
"    In addition to faulty care processes in the operating room, the American College of Surgeons (ACS) acknowledges that poor communication among perioperative care personnel plays an important role in retained foreign bodies. One ACS editorial cites examples of poor communication such as surgeons dismissing reports of a miscount as an error and multiple intraoperative personnel changes without accurate cross-informational reporting [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26105/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8420783\">",
"    <span class=\"h1\">",
"     NATIONAL MANDATE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2002 National Quality Forum listed retained items among a group of completely preventable medical errors that should never happen to patients, the so-called &ldquo;never events.&rdquo; Retained surgical materials are also considered &ldquo;always wrong&rdquo; by the Leapfrog initiative, mandating acknowledgement, direct apology to the patient, and hospital payment for all costs incurred as a result.",
"   </p>",
"   <p>",
"    In 2005, the Joint Commission for the Accreditation of Hospitals (JCAHO) designated retained surgical items as sentinel events requiring immediate investigation and response. As of 2008, the Centers for Medicare and Medicaid Services deny reimbursement to hospitals for the costs associated with objects left in patients during an operation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H251482812\">",
"    <span class=\"h1\">",
"     PREVENTION STRATEGIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Strategies for preventing retained surgical foreign bodies are directed at patient care processes and the work environment in the operating room. Unfortunately, no prevention strategy is entirely foolproof and each is associated with advantages and disadvantages.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H251482826\">",
"    <span class=\"h2\">",
"     Care processes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Faulty care processes with the potential to cause retained surgical foreign bodies include poorly performed sponge and instrument counts, inadequate or incomplete wound explorations, and incomplete, inadequate, or misinterpreted intraoperative radiographs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H251482840\">",
"    <span class=\"h3\">",
"     Standardized count protocols",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mainstay of preventing retained sponge is the surgical count. Instruments are also counted. All sponges used during surgical procedures should contain radiopaque indicators.",
"   </p>",
"   <p>",
"    In 2006, the Association of Operating Room Nurses (AORN) published an updated recommended practices policy. This practice policy is widely used and nationally recognized as the gold standard for counting policies in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26105/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Specifically, sponge counts are performed at the following points during the procedure:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Before the procedure begins",
"     </li>",
"     <li>",
"      At the time of permanent relief of a scrub nurse or circulating nurse",
"     </li>",
"     <li>",
"      Before closure of a body cavity",
"     </li>",
"     <li>",
"      Before wound closure begins",
"     </li>",
"     <li>",
"      At skin closure or end of the procedure",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Sponges should be separated,",
"    <strong>",
"     audibly",
"    </strong>",
"    counted, and concurrently viewed during the count procedure by two individuals, typically the scrub nurse and circulating nurse. If a discrepancy in any of the counts is identified, the entire surgical team is responsible for carrying out appropriate steps to locate the missing item. The odds of a retained foreign body are increased 100-fold if there is a persistent discrepancy between the initial and final sponge counts [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26105/abstract/7,22\">",
"     7,22",
"    </a>",
"    ]. If the item cannot be found with manual exploration of the surgical site by the surgeon or cannot be located elsewhere in the room (eg, trash), an intraoperative radiograph should be taken before final closure of the body cavity. The film should be read by a staff radiologist who has been specifically alerted that the purpose of the film is to &ldquo;rule out retained foreign body.&rdquo;",
"    <strong>",
"     Before",
"    </strong>",
"    anesthesia is reversed, the radiologist should communicate the results of the film reading to the responsible surgeon,",
"    <strong>",
"     and",
"    </strong>",
"    confirm that the entire surgical field (abdominal, pelvic or other body cavity) has been included in the film [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26105/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H251482889\">",
"     'Radiographic screening'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Despite widespread compliance with the convention of the surgical count, data are inconclusive regarding its effectiveness in reducing the risk of a retained surgical foreign body. Unfortunately, an incorrect count does not mean that a retained foreign body is present, and more importantly, a correct count may be erroneous and is therefore not a guarantee of the absence of a retained foreign body. (See",
"    <a class=\"local\" href=\"#H93794279\">",
"     'Count discrepancies'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H93794279\">",
"    <span class=\"h3\">",
"     Count discrepancies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical counts are subject to human error. Up to 88 percent of retained foreign body cases occur in the face of sponge and instrument counts that were declared &ldquo;correct&rdquo; [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26105/abstract/7\">",
"     7",
"    </a>",
"    ]. The initial count at the beginning of the procedure may be wrong or an interim count may have been rushed while nursing teams were changing shifts, or in some cases the count is omitted altogether as may occur during emergency laparotomy. Other factors related to the operating room environment that contribute to count discrepancy include incomplete, interrupted, or absent sponge counts, absence of a clear standardized count policy, and using nonradiopaque sponges [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26105/abstract/11,19\">",
"     11,19",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Count discrepancies should",
"    <strong>",
"     never",
"    </strong>",
"    be dismissed as human error but should instead prompt a thorough search for the missing items and count reconciliation.",
"   </p>",
"   <p>",
"    The frequency of count discrepancies has been evaluated in several studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study at a major academic medical center examined the frequency of disparities in the final surgical count over a four-year period [",
"      <a class=\"abstract\" href=\"UTD.htm?25/31/26105/abstract/24\">",
"       24",
"      </a>",
"      ]. Count discrepancies were found in 1062 of 153,263 surgical procedures for a counting error rate of 0.7 percent. Among the discrepancies, the missing item was found in 51 of the 1062 cases with 34 found in the operating room and 17 found in the patient. The positive predictive value of a discrepant count leading to a retained foreign body with was only 1.6 percent. The authors noted that the frequency of &ldquo;false positive&rdquo; discrepant counts may be the fundamental source of surgeon skepticism of sponge and instrument counts, thereby reducing the impact of what should be an alarm signal when an incorrect count occurs.",
"     </li>",
"     <li>",
"      In another report, at least one count discrepancy occurred in 12.8 percent of 148 operations (approximately one of eight operations); 41 percent of the discrepancies were due to process errors including miscounts, mathematical errors or documentation problems, and 59 percent due to a misplaced sponge or instrument [",
"      <a class=\"abstract\" href=\"UTD.htm?25/31/26105/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A common concern is that the counting protocol itself may pose a threat to patient safety by distracting the surgical team from primary activities, particularly during more complex procedures. During interim counts, the surgical procedure is ongoing, and the scrub nurse and circulating nurse must perform the count while carrying out other duties.",
"   </p>",
"   <p>",
"    In a study that detailed activities during nine complex general surgery cases performed in an academic hospital, counting was an auxiliary task that was in direct competition with primary patient-centered activities [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26105/abstract/26\">",
"     26",
"    </a>",
"    ]. An average of 35 minutes per case was dedicated to counting, representing 14.5 percent of the nursing time during the operation. In spite of the time involved, 17 count discrepancies were observed, 11 of which disrupted the activities of the surgical team. The observational team identified two events labeled as &ldquo;safety-compromising&rdquo; that occurred when attempts were being made to reconcile an inconsistent count.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H251482889\">",
"    <span class=\"h3\">",
"     Radiographic screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;The limitations of the surgical count in preventing retained surgical foreign bodies have necessitated the use of radiography to identify surgical foreign bodies. The diagnostic features of retained surgical foreign body on plain radiography are discussed below. (See",
"    <a class=\"local\" href=\"#H93794279\">",
"     'Count discrepancies'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H251482861\">",
"     'Imaging'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Plain abdominal films can be obtained in all patients, independent of the results of the surgical count, or selectively obtained based upon the persistence of an incorrect count.",
"   </p>",
"   <p>",
"    In a study that involved 191,168 surgical patients, the protocol included a high-resolution survey radiograph performed in a dedicated radiology suite after the patient left the operating room (but before transport to the recovery room) regardless of whether a radiograph was performed by a portable machine in the operating room [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26105/abstract/8\">",
"     8",
"    </a>",
"    ]. A retained foreign body was found in 34 of the patients (0.02 percent), 20 of whom had a count that was deemed correct. Of the 34 patients, 18 had undergone intraoperative radiography with a portable machine that did not demonstrate the foreign body in six of the patients, stressing the importance of high-resolution radiography. On the other hand, the cost of routine high-resolution radiographs may be prohibitive and radiation exposure is also a concern [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26105/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One trauma center&rsquo;s experience with retained sponges highlights the experience at one institution with sponge counts and screening for retained foreign bodies using intraoperative radiography (or lack thereof). Three cases of retained sponge occurred over a two-year period [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26105/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Case 1: During open abdominal exploration, the abdomen was packed to control bleeding followed by multiple returns to the operating room by different surgical teams. The institution had no policy for documenting and accounting for abdominal packs intentionally left in the abdomen during damage control surgery. The patient&rsquo;s abdominal wound healed by secondary intention. The patient returned six weeks after discharge with wound drainage that was found on CT scan to have a retained sponge. The policy was revised to require radiography after every procedure and reading of the film by a physician trained to recognize the characteristics of a retained sponge.",
"     </li>",
"     <li>",
"      Case 2: A little more than one year later, a patient with hemoperitoneum from an abdominal crush injury underwent emergent laparotomy and packing. The bleeding was controlled, sponge counts were correct, and the mandatory abdominal radiograph was performed and was negative for a retained foreign body. CT scan performed for another reason identified a retained sponge near the spleen. It was evident upon review of the intraoperative radiograph, that the left side of the patient&rsquo;s abdomen was only partially imaged due to a misplaced film cartridge. This incident prompted revision of the policy to include immediate notification of the operating surgeon if the intraoperative radiograph did not cover the entire surgical field. &nbsp;",
"     </li>",
"     <li>",
"      Case 3: Four months later, a young blunt trauma victim required emergent laparotomy and damage control packing. The patient was returned to the operating room two days later for re-exploration, removal of the packs, and fascial closure. The sponge counts were correct, the abdominal radiography was judged to be adequate and negative for retained sponge by the attending surgeon. Nevertheless, a sponge was identified in the left upper quadrant on a subsequent plain abdominal film. The tip of the retained sponge was visible on the original plain film and the film &lsquo;clipped&rsquo; only slightly. This finding was missed by multiple subsequent reviewers.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H251482847\">",
"    <span class=\"h2\">",
"     Counting devices",
"    </span>",
"    &nbsp;&mdash;&nbsp;Counting devices are another approach to materials management that involves tagging items used in cavitary surgery with bar codes or radiofrequency chips. The hope is that these newer technologies will eliminate the need for radiographs and more reliably identify retained surgical foreign bodies. However, both technologies significantly increase cost. (See",
"    <a class=\"local\" href=\"#H251484200\">",
"     'Cost'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Bar codes are used primarily to assist with counting. One trial randomly assigned 300 patients undergoing a general surgical procedure to a bar-coded sponge counting system or traditional counting [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26105/abstract/28\">",
"     28",
"    </a>",
"    ]. In the bar-coded arm, sponges were scanned as they were added to the sterile field, and again as they were removed. The bar-code system detected significantly more counting discrepancies than the traditional counting (32 versus 13 sponges). Although the bar-code system improved the recognition of missing sponges, the amount of time required to resolve discrepancies and the need for a radiograph to resolve a discrepancy was not changed. Disadvantages of the bar-coded sponge system were a significantly greater amount of time spent counting sponges compared with the traditionally counted sponges, and increased cost.",
"   </p>",
"   <p>",
"    Another approach uses radiofrequency identification (RFID) tags or microchips that can be detected inside the patient [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26105/abstract/29\">",
"     29",
"    </a>",
"    ]. At the completion of the procedure but prior to closure, a handheld radio wand connected to a detection console is passed over the patient and, if the chip on a tagged item is detected during the radio query, a digital or audio alarm is triggered.",
"   </p>",
"   <p>",
"    RFID scanning is superior to abdominal radiography for the detection of retained surgical foreign bodies with sensitivity and specificities that are reliably 100 percent when the system is properly used, even in patients who are morbidly obese [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26105/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. RFID sponge detection is rapid; in one study, intentionally placed sponges were detected in an average of less than 3 seconds [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26105/abstract/30\">",
"     30",
"    </a>",
"    ]. A disadvantage of RFID is potential compromise of medical device function (eg, pacemaker, infusion pump, mechanical ventilator) due to electromagnetic interference (EMI) from the radio waves. The risk appears to depend upon the frequency and mode of the RFID tagging system [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26105/abstract/32\">",
"     32",
"    </a>",
"    ]. Despite the potential risk with RFID scanning, there have been no incident reports to the Food and Drug Administration of the United States (FDA) of clinically significant interference with pacemaker or implantable cardioverter-defibrillator devices [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26105/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H251484200\">",
"    <span class=\"h2\">",
"     Cost",
"    </span>",
"    &nbsp;&mdash;&nbsp;The choice of preventive strategy depends upon the resources of the facility, ease of use, workflow issues, priorities, and perception of the consequences of retained surgical foreign objects, which all have a bearing on cost [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26105/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A cost-effectiveness study of emergent open cavity surgery found that routine intraoperative radiography was the preferred strategy compared with standard surgical counts alone provided that the sensitivity of standard counting is less than 98 percent and that legal fees are more than $44,000 per case of retained sponge [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26105/abstract/35\">",
"     35",
"    </a>",
"    ]. However, this model requires accurate radiography performance and interpretation. (See",
"    <a class=\"local\" href=\"#H93794279\">",
"     'Count discrepancies'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H251482889\">",
"     'Radiographic screening'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Another approach used a decision analysis simulation to model the predicted incidence of retained sponge and the incremental costs associated with various prevention strategies [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26105/abstract/34\">",
"     34",
"    </a>",
"    ]. For a sponge tracking strategy to be cost-effective, it must come very close to eliminating retained foreign bodies while keeping incremental costs low given that retained foreign bodies are rare. The authors estimated the average cost of a retained sponge at $200,000 per event. The baseline incidence of retained sponge associated with a standard counting protocol alone was estimated to be 12 per 100,000 cases. To be cost saving when compared with the expected losses, a strategy that completely eliminates the incidence of retained sponge would need to cost less than $24 per operation.",
"   </p>",
"   <p>",
"    Using this model, the following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Universal and selective use of radiographs were each estimated to cost more than $1,000,000 per event prevented compared with standard counting protocols.",
"     </li>",
"     <li>",
"      The radiofrequency-tagged sponge system, even under the assumption that it would prevent 100 percent of retained sponge events, was estimated to cost $620,000 per event prevented.",
"     </li>",
"     <li>",
"      Using a bar-coded sponge system and assuming the incidence of retained sponge using bar coding would be no more than 1.7 per 100,000, the cost was approximately $95,000 per event prevented.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H251482922\">",
"    <span class=\"h2\">",
"     Work environment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Communication in the operating room is particularly relevant to the problem of retained surgical foreign body and the American College of Surgeons emphasizes team development and team performance in promoting a culture of patient safety [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26105/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H251481323\">",
"     'Risk factors'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Distractions including interruptions, noise, conversation, and traffic in the operating room should be limited. When personnel changes occur during a procedure, complete and accurate transmission of relevant information about the surgical field and its contents needs to be conveyed. Focused time for these tasks, and particularly the surgical count, should reduce errors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H251482854\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Retained surgical sponge results in a broad spectrum of clinical presentations [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26105/abstract/36\">",
"     36",
"    </a>",
"    ]. The reported time to diagnosis ranges from 1 day to 40 years [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26105/abstract/11,37\">",
"     11,37",
"    </a>",
"    ]. In a series of 14 cases of retained surgical foreign body in the abdomen at a single institution over a six-year period, all but one patient were symptomatic at presentation; abdominal pain was the most common symptom [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26105/abstract/37\">",
"     37",
"    </a>",
"    ]. In general, two distinct clinical patterns of retained surgical sponge are described: exudative and fibrinous [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26105/abstract/37-39\">",
"     37-39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H251483055\">",
"    <span class=\"h2\">",
"     Exudative",
"    </span>",
"    &nbsp;&mdash;&nbsp;The early or exudative pattern usually presents in the postoperative period as a result of local inflammation as a response to the foreign body.",
"   </p>",
"   <p>",
"    The most common clinical sign associated with retained surgical sponge in the immediate postoperative period is surgical site infection [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26105/abstract/40\">",
"     40",
"    </a>",
"    ]. Although sponges themselves are sterile, any inoculation (skin, gastrointestinal flora) permits bacteria to reproduce in the interstices of the sponge (inaccessible to immune mechanisms), which may result in wound infection, abscess, fistula formation, or sepsis. Approximately 10 to 15 percent of cases of retained surgical sponge are complicated by acute intraabdominal sepsis, which is associated with high morbidity [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26105/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. Longer retention times increase the risk of bowel fistulization.",
"   </p>",
"   <p>",
"    Other clinical presentations involve extrusion of the sponge which can occur externally through the wound or by fistulization into the rectum, vagina, or bladder. Sponge erosion and migration internally can lead to intestinal obstruction, malabsorption or gastrointestinal hemorrhage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H251483062\">",
"    <span class=\"h2\">",
"     Fibrinous",
"    </span>",
"    &nbsp;&mdash;&nbsp;A fibrinous pattern refers to the encapsulation of the retained foreign object within scar tissue, which presents in a delayed fashion (&gt;60 days) representing about 25 percent of all cases. Delayed presentations months, years, or, in some cases, decades later following the index surgical procedure have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26105/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The fibrinous clinical pattern presents as a soft tissue mass in about 27 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26105/abstract/11\">",
"     11",
"    </a>",
"    ], or as an aseptic foreign body granuloma with adhesions and encapsulation with &ldquo;pseudotumor&rdquo; formation. Some may mimic carcinoma, leading to ill-advised attempts at biopsy or radical excision of involved organs en bloc.",
"   </p>",
"   <p>",
"    Patients with an abdominal or pelvic retained surgical sponge may have nonspecific symptoms such as chronic abdominal pain, nausea, dyspepsia, constipation, weight loss, and pelvic pressure. A pulmonary retained surgical sponge may cause shoulder pain, cough, hemoptysis or chest pain [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26105/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most common presentation of a retained surgical sponge in an extremity is a soft tissue mass which can be mistaken for a sarcoma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H251482861\">",
"    <span class=\"h1\">",
"     IMAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of a retained surgical foreign body is based upon imaging studies that demonstrate the object. If retained surgical foreign body is suspected in the immediate postoperative period, plain radiographs of the surgical field should be performed. Radiopaque surgical instruments and devices should be immediately apparent on plain film and the characteristic appearance of radiopaque tape or wires of laparotomy pads and surgical sponges, respectively, should indicate their presence.",
"   </p>",
"   <p>",
"    Over time, radiopaque markers may fragment or disintegrate altogether [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26105/abstract/42\">",
"     42",
"    </a>",
"    ]. Thus, for patients with symptoms potentially due to retained sponge from a past surgery, we prefer computed tomography as the initial study. (See",
"    <a class=\"local\" href=\"#H733684534\">",
"     'Computed tomography'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Of asymptomatic retained sponges, about 6 percent are discovered on routine imaging studies performed for other reasons. Many modalities have identified retained sponges incidentally including mammography, ultrasound, magnetic resonance imaging and fluorodeoxyglucose positron emission tomography.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H733684518\">",
"    <span class=\"h2\">",
"     Plain film",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plain radiographs are the most common imaging technique used to detect retained sponges. The accuracy of plain radiography in detecting retained sponge is not very high and it is important to keep in mind that most missed retained sponges are at the edges of the film. These issues are discussed above. (See",
"    <a class=\"local\" href=\"#H251482889\">",
"     'Radiographic screening'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    A retained sponge appears opaque on plain radiograph with mottled small air densities (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef82578 \" href=\"UTD.htm?30/25/31121\">",
"     image 1",
"    </a>",
"    ). If the sponge still contains a radiopaque marker, the diagnosis may be made based upon the characteristic appearance of wavy striped lines.",
"   </p>",
"   <p>",
"    On chest radiograph, intrathoracic retained surgical sponge may mimic intrapulmonary abscess, aspergilloma, or tumor. Retained surgical sponge adjacent to bone may show a periosteal reaction [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26105/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Known causes of false-negative radiographs include poor film quality, multiple other radiopaque densities, and a lack of awareness on the radiologist&rsquo;s part that there was a concern for retained foreign body [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26105/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H733684662\">",
"    <span class=\"h2\">",
"     Gastrointestinal contrast studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although computed tomography is the test of choice to evaluate suspected retained surgical foreign body, gastrointestinal studies performed to evaluate abdominal symptoms may show the retained object as the source of obstruction or fistula formation. Intraluminal retained sponges will appear as a whorl-like hypodense mass with a thick rim (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef73101 \" href=\"UTD.htm?15/18/15651\">",
"     image 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H733684534\">",
"    <span class=\"h2\">",
"     Computed tomography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Computed tomography (CT) scan is superior to plain radiograph for evaluating the source of symptoms and detecting retained surgical sponge [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26105/abstract/38\">",
"     38",
"    </a>",
"    ]. The most characteristic appearance of retained sponge is a low-density heterogeneous mass with a spongiform pattern that contains gas bubbles. The mass may contain wavy striped high-density areas that represent the markers. Very long-standing retained surgical sponge on CT is associated with calcification due to gradual calcium deposition along the fiber network of the surgical gauze, also known as the calcified reticulate rind sign (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef61325 \" href=\"UTD.htm?41/49/42769\">",
"     image 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26105/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H733684541\">",
"    <span class=\"h2\">",
"     Other modalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Depending upon the nature of the surgical intervention, a retained surgical foreign body may be identified using other modalities including mammography (eg, breast surgery), ultrasound (eg, extremity surgery), and magnetic resonance (MR) imaging (eg, spinal surgery).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The ultrasound appearance of a retained sponge may result in a cystic, solid or combined appearance. Ultrasound typically demonstrates a well-delineated mass with wavy internal echoes and dense acoustic shadowing behind the object (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef59958 \" href=\"UTD.htm?40/10/41121\">",
"       image 4",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?25/31/26105/abstract/38\">",
"       38",
"      </a>",
"      ]. Prolonged retention is characterized by an encapsulating hypoechoic complex pseudotumor, with both cystic and solid components.",
"     </li>",
"     <li>",
"      Magnetic resonance imaging of a retained sponge appears as a soft-tissue-density mass with a thick, well-defined capsule (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef71741 \" href=\"UTD.htm?30/35/31285\">",
"       image 5",
"      </a>",
"      ); the signal intensity varies according to histologic composition, stage, and fluid content of the retained surgical sponge [",
"      <a class=\"abstract\" href=\"UTD.htm?25/31/26105/abstract/38\">",
"       38",
"      </a>",
"      ]. A whorled internal configuration is seen on T2-weighted imaging. In general, most lesions caused by foreign bodies are hypointense on T1-weighted images and hyperintense on T2-weighted images [",
"      <a class=\"abstract\" href=\"UTD.htm?25/31/26105/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Uptake on fluorodeoxyglucose positron emission tomography (FDG-PET) imaging corresponds to the fibroblastic reaction and encapsulation of the sponge and appears as a characteristic rim-shaped uptake with a central region with no uptake (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef50655 \" href=\"UTD.htm?19/20/19781\">",
"       image 6",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?25/31/26105/abstract/41,42\">",
"       41,42",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H251482868\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once a retained sponge is identified in the",
"    <strong>",
"     symptomatic",
"    </strong>",
"    patient, it should be removed [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26105/abstract/7,20,44\">",
"     7,20,44",
"    </a>",
"    ]. However, operative removal of retained sponges, particularly those present for a prolonged time, can be difficult and is associated with high complication rates. The mortality associated with retained sponges ranges from 11 to 35 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26105/abstract/45\">",
"     45",
"    </a>",
"    ]. Most intraabdominal retained foreign bodies require laparotomy for removal; however, laparoscopic removal has been described for both retained instruments and sponges [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26105/abstract/46,47\">",
"     46,47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a review of 14 cases of retained surgical sponge at a single institution over a six-year period, four of the patients required urgent surgery due to symptoms of intestinal obstruction or intraabdominal sepsis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26105/abstract/37\">",
"     37",
"    </a>",
"    ]. Following removal of the sponge, 5 of the 14 patients developed postoperative complications.",
"   </p>",
"   <p>",
"    Although removal of the retained surgical object should be pursued in symptomatic patients, there may be a role for watchful waiting in selected",
"    <strong>",
"     asymptomatic",
"    </strong>",
"    patients, particularly if there has been a prolonged retention time [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26105/abstract/4\">",
"     4",
"    </a>",
"    ]. In one case series, a decision was made not to attempt removal of 6 out of 34 asymptomatic retained surgical foreign bodies, primarily because it was felt that the procedure to remove the object would pose a greater risk than leaving it in place [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26105/abstract/8\">",
"     8",
"    </a>",
"    ]. The authors did not report on the long-term outcomes of the patients or the character or location of the items left behind.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H251482875\">",
"    <span class=\"h1\">",
"     MEDICOLEGAL IMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Retained surgical materials are considered &ldquo;always wrong,&rdquo; mandating acknowledgement, direct apology to the patient, and hospital payment for all costs incurred as a result. (See",
"    <a class=\"local\" href=\"#H8420783\">",
"     'National mandate'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The ramifications for surgical team members include malpractice lawsuits and adverse reports to the state licensing boards or National Practitioner Data Bank. In most jurisdictions, the legal doctrine applied to the problem of a retained surgical sponge is res ipsa loquitor, &ldquo;the thing speaks for itself&rdquo;. The fact that a surgical foreign object has been retained is, in itself, proof that malpractice has occurred. It is also important to note that the statutes of limitations for retained foreign body in most jurisdictions are generally extended indefinitely, rather than fixed to a two or three-year term as in other cases of medical malpractice. Thus, one may be able to sue 20 years later for a foreign body that was undiscovered.",
"   </p>",
"   <p>",
"    In a review of closed case files in Massachusetts, 40 patients were found to have retained sponges over a seven-year period representing about half of the claims of retained foreign bodies during that period [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26105/abstract/48\">",
"     48",
"    </a>",
"    ]. Eleven were vaginal sponges retained after vaginal delivery, and these were presumably removed at the bedside, without requiring laparotomy. Total compensatory damage awards for the 40 actions were $2,072,318, with $1,762,163 (85 percent) made on behalf of the surgeon and $909,705 (15 percent) on behalf of the health care institution. Five cases (10 percent) went to trial. A median of $68,857 and a mean of $32,500 were spent on claims involving abdominal procedures. The time period between discovery of the sponge and the original procedure was significantly related to the case payment, with higher payments reflecting delayed discovery and difficulties and complications associated with surgical removal. Two patients declined removal of the retained sponge because they were asymptomatic, but filed claims for damages anyway.",
"   </p>",
"   <p>",
"    In several cases, a verdict has been returned against the surgeon in spite of a correct sponge count [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26105/abstract/49\">",
"     49",
"    </a>",
"    ]. The surgeon can be held responsible for his or her own failure to examine the field and look",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    feel for foreign bodies independent of the staff&rsquo;s responsibility to perform accurate counts. The duties are parallel, and one responsibility does not relieve the other.",
"   </p>",
"   <p>",
"    Payments for claims for retained sponges may be greater in jurisdictions where no cap on noneconomic damages exists. Among three studies, the average payment for retained surgical foreign body was estimated at $95,000, a figure that included $14,701 for readmission and reoperation and the remainder in lost wages and",
"    <span class=\"nowrap\">",
"     pain/suffering.",
"    </span>",
"    In a review of over 1000 cases reported to the National Practitioner Data Bank over a seven-year period, retained surgical foreign body resulted in a mean compensation of $77,175. The maximum payment was $2,350,000 [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26105/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H251480787\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most common retained surgical foreign body is a surgical sponge, also known as gossypiboma. Retained surgical sponges and other surgical foreign bodies unintentionally left at surgical sites are rare medical errors that have the potential to cause significant harm to the patient. Retained items are among a group of completely preventable medical errors that are always considered wrong. (See",
"      <a class=\"local\" href=\"#H251480748\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8420783\">",
"       'National mandate'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A retained surgical foreign body is related to the patient care processes and the work environment in the operating room. Many factors have been associated with retained surgical foreign body. Factors identified as significantly contributing to increased risk include the following (see",
"      <a class=\"local\" href=\"#H251481323\">",
"       'Risk factors'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Emergency surgical procedures (risk ratio [RR] 8.8, 95% CI 2.4-31.9)",
"     </li>",
"     <li>",
"      Unexpected change in the course of a surgical procedure (RR 4.1, 95% CI 1.4-12.4)",
"     </li>",
"     <li>",
"      Increased body mass index (RR per one-unit increment 1.1, 95% CI 1.0-1.2)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Strategies for preventing a retained surgical foreign body are directed at patient care processes in the operating room including improving the accuracy of surgical counts and improving communication between the members of the surgical team. Tracking devices that use electronic tagging increase the accuracy of sponge counts (bar coding) and reliably identify retained sponges (radiofrequency identification), but these technologies are costly, and thus, have not been widely adopted. (See",
"      <a class=\"local\" href=\"#H251482812\">",
"       'Prevention strategies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The best strategy to prevent retained foreign body depends upon institutional resources, operating room workflow, and perception of the consequences of retained surgical foreign objects relative to cost. Given the limitations of the surgical count, particularly under emergency circumstances, we prefer to obtain a radiograph of the operative field (open cavity surgery) prior to patient transport in high-risk patients. In patients with a low risk for retained surgical foreign object, we employ selective radiographic screening. (See",
"      <a class=\"local\" href=\"#H251482889\">",
"       'Radiographic screening'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Two distinct clinical patterns of retained surgical sponges are described. An exudative pattern, characterized by wound complications including infection, abscess or fistula formation, usually presents early in the postoperative period. Expulsion of the sponge can occur externally through the wound, or fistula tract to the rectum, vagina, bladder or internally leading to intestinal obstruction, malabsorption or gastrointestinal hemorrhage. A delayed or fibrinous clinical pattern usually presents with nonspecific symptoms and findings of a soft tissue mass or aseptic foreign body granuloma with adhesions and encapsulation of the sponge. (See",
"      <a class=\"local\" href=\"#H251482854\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of a retained surgical foreign body is based upon imaging studies that demonstrate the object. Surgical instruments are readily apparent on imaging studies. The appearance of retained surgical sponge on imaging depends upon the retention time and modality chosen. In the majority of patients, symptoms indicate the need for imaging, but in about 6 percent of patients, the retained sponge is discovered incidentally. Very long-standing retained surgical sponge is associated with a particular pattern of calcification termed the reticulate rind sign. (See",
"      <a class=\"local\" href=\"#H251482861\">",
"       'Imaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We remove all symptomatic retained surgical foreign bodies. There may be a role for observational management in asymptomatic patients, particularly if the retention time has been prolonged, given that operative removal of retained sponges can be difficult and is associated with significant morbidity and mortality. (See",
"      <a class=\"local\" href=\"#H251482868\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The medicolegal ramifications of retained surgical foreign body for the surgeon can be significant. The fact that an instrument or sponge has been left behind is considered proof that malpractice has occurred. Compensatory damage awards are commonly assigned to the surgeon as well as the hospital who is the employer of the operating room staff. (See",
"      <a class=\"local\" href=\"#H251482875\">",
"       'Medicolegal implications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26105/abstract/1\">",
"      Lincourt AE, Harrell A, Cristiano J, et al. Retained foreign bodies after surgery. J Surg Res 2007; 138:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26105/abstract/2\">",
"      Williams RG, Bragg DG, Nelson JA. Gossypiboma--the problem of the retained surgical sponge. Radiology 1978; 129:323.",
"     </a>",
"    </li>",
"    <li>",
"     Quinion M. World Wide Words. Copyright 1996-2011. file://www.worldwidewords.org/weirdwords/ww-gos1.htm (Accessed on October 20, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26105/abstract/4\">",
"      Berkowitz S, Marshall H, Charles A. Retained intra-abdominal surgical instruments: time to use nascent technology? Am Surg 2007; 73:1083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26105/abstract/5\">",
"      Ahmed F, Swan MC, Flynn M, Tiernan EP. Retained VAC therapy sponge as a complication of abdominoplasty. J Plast Reconstr Aesthet Surg 2010; 63:e497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26105/abstract/6\">",
"      Leijnen M, Steenvoorde P, van Doorn LP, et al. A non-healing sinus of the lower leg 5 years after vacuum-assisted closure therapy due to a gossypiboma. Wounds 2007; 19:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26105/abstract/7\">",
"      Gawande AA, Studdert DM, Orav EJ, et al. Risk factors for retained instruments and sponges after surgery. N Engl J Med 2003; 348:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26105/abstract/8\">",
"      Cima RR, Kollengode A, Garnatz J, et al. Incidence and characteristics of potential and actual retained foreign object events in surgical patients. J Am Coll Surg 2008; 207:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26105/abstract/9\">",
"      Hyslop JW, Maull KI. Natural history of the retained surgical sponge. South Med J 1982; 75:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26105/abstract/10\">",
"      Teixeira PG, Inaba K, Salim A, et al. Retained foreign bodies after emergent trauma surgery: incidence after 2526 cavitary explorations. Am Surg 2007; 73:1031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26105/abstract/11\">",
"      Wan W, Le T, Riskin L, Macario A. Improving safety in the operating room: a systematic literature review of retained surgical sponges. Curr Opin Anaesthesiol 2009; 22:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26105/abstract/12\">",
"      Naama O, Quamous O, Elasri CA, et al. Textiloma: an uncommon complication of posterior lumbar surgery. J Neuroradiol 2010; 37:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26105/abstract/13\">",
"      Mouhsine E, Halkic N, Garofalo R, et al. Soft-tissue textiloma: a potential diagnostic pitfall. Can J Surg 2005; 48:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26105/abstract/14\">",
"      Kim AK, Lee EB, Bagley LJ, Loevner LA. Retained surgical sponges after craniotomies: imaging appearances and complications. AJNR Am J Neuroradiol 2009; 30:1270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26105/abstract/15\">",
"      Haegeman S, Maleux G, Heye S, Daenens K. Textiloma complicated by abscess-formation, three years after surgical repair of abdominal aortic aneurysm. JBR-BTR 2008; 91:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26105/abstract/16\">",
"      El Khoury M, Mignon F, Tardivon A, et al. Retained surgical sponge or gossypiboma of the breast. Eur J Radiol 2002; 42:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26105/abstract/17\">",
"      Camp M, Chang DC, Zhang Y, et al. Risk factors and outcomes for foreign body left during a procedure: analysis of 413 incidents after 1 946 831 operations in children. Arch Surg 2010; 145:1085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26105/abstract/18\">",
"      Song SY, Hong JW, Yoo WM, Tark KC. Gossypiboma after mandibular contouring surgery. J Craniofac Surg 2009; 20:1607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26105/abstract/19\">",
"      Stawicki SP, Evans DC, Cipolla J, et al. Retained surgical foreign bodies: a comprehensive review of risks and preventive strategies. Scand J Surg 2009; 98:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26105/abstract/20\">",
"      Gibbs VC, McGrath MH, Russell TR. The prevention of retained foreign bodies after surgery. Bull Am Coll Surg 2005; 90:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26105/abstract/21\">",
"      Jackson S, Brady S. Counting difficulties: retained instruments, sponges, and needles. AORN J 2008; 87:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26105/abstract/22\">",
"      Greenberg CC, Gawande AA. Beyond counting: current evidence on the problem of retaining foreign bodies in surgery? Ann Surg 2008; 247:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26105/abstract/23\">",
"      AORN Recommended Practices Committee. Recommended practices for sponge, sharps, and instrument counts. AORN J 2006; 83:418, 421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26105/abstract/24\">",
"      Egorova NN, Moskowitz A, Gelijns A, et al. Managing the prevention of retained surgical instruments: what is the value of counting? Ann Surg 2008; 247:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26105/abstract/25\">",
"      Greenberg CC, Regenbogen SE, Lipsitz SR, et al. The frequency and significance of discrepancies in the surgical count. Ann Surg 2008; 248:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26105/abstract/26\">",
"      Christian CK, Gustafson ML, Roth EM, et al. A prospective study of patient safety in the operating room. Surgery 2006; 139:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26105/abstract/27\">",
"      McIntyre LK, Jurkovich GJ, Gunn ML, Maier RV. Gossypiboma: tales of lost sponges and lessons learned. Arch Surg 2010; 145:770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26105/abstract/28\">",
"      Greenberg CC, Diaz-Flores R, Lipsitz SR, et al. Bar-coding surgical sponges to improve safety: a randomized controlled trial. Ann Surg 2008; 247:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26105/abstract/29\">",
"      Westra BL. Radio frequency identification. Am J Nurs 2009; 109:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26105/abstract/30\">",
"      Macario A, Morris D, Morris S. Initial clinical evaluation of a handheld device for detecting retained surgical gauze sponges using radiofrequency identification technology. Arch Surg 2006; 141:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26105/abstract/31\">",
"      Steelman VM. Sensitivity of detection of radiofrequency surgical sponges: a prospective, cross-over study. Am J Surg 2011; 201:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26105/abstract/32\">",
"      van der Togt R, van Lieshout EJ, Hensbroek R, et al. Electromagnetic interference from radio frequency identification inducing potentially hazardous incidents in critical care medical equipment. JAMA 2008; 299:2884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26105/abstract/33\">",
"      Seidman SJ, Brockman R, Lewis BM, et al. In vitro tests reveal sample radiofrequency identification readers inducing clinically significant electromagnetic interference to implantable pacemakers and implantable cardioverter-defibrillators. Heart Rhythm 2010; 7:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26105/abstract/34\">",
"      Regenbogen SE, Greenberg CC, Resch SC, et al. Prevention of retained surgical sponges: a decision-analytic model predicting relative cost-effectiveness. Surgery 2009; 145:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26105/abstract/35\">",
"      Dossett LA, Dittus RS, Speroff T, et al. Cost-effectiveness of routine radiographs after emergent open cavity operations. Surgery 2008; 144:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26105/abstract/36\">",
"      Rappaport W, Haynes K. The retained surgical sponge following intra-abdominal surgery. A continuing problem. Arch Surg 1990; 125:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26105/abstract/37\">",
"      Yildirim S, Tarim A, Nursal TZ, et al. Retained surgical sponge (gossypiboma) after intraabdominal or retroperitoneal surgery: 14 cases treated at a single center. Langenbecks Arch Surg 2006; 391:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26105/abstract/38\">",
"      Manzella A, Filho PB, Albuquerque E, et al. Imaging of gossypibomas: pictorial review. AJR Am J Roentgenol 2009; 193:S94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26105/abstract/39\">",
"      Vallerie AM, Herzog TJ, Wright JD. Postpartum sterilization: small incision, big complication. Obstet Gynecol 2008; 112:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26105/abstract/40\">",
"      Deger RB, LiVolsi VA, Noumoff JS. Foreign body reaction (gossypiboma) masking as recurrent ovarian cancer. Gynecol Oncol 1995; 56:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26105/abstract/41\">",
"      Vento JA, Karak PK, Henken EM. Gossypiboma as an incidentaloma. Clin Nucl Med 2006; 31:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26105/abstract/42\">",
"      Yuh-Feng T, Chin-Chu W, Cheng-Tau S, Min-Tsung T. FDG PET CT features of an intraabdominal gossypiboma. Clin Nucl Med 2005; 30:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26105/abstract/43\">",
"      Kim CK, Park BK, Ha H. Gossypiboma in abdomen and pelvis: MRI findings in four patients. AJR Am J Roentgenol 2007; 189:814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26105/abstract/44\">",
"      Shyung LR, Chang WH, Lin SC, et al. Report of gossypiboma from the standpoint in medicine and law. World J Gastroenterol 2005; 11:1248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26105/abstract/45\">",
"      Lauwers PR, Van Hee RH. Intraperitoneal gossypibomas: the need to count sponges. World J Surg 2000; 24:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26105/abstract/46\">",
"      Singh R, Mathur RK, Patidar S, Tapkire R. Gossypiboma: its laparoscopic diagnosis and removal. Surg Laparosc Endosc Percutan Tech 2004; 14:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26105/abstract/47\">",
"      Rodrigues D, Perez NE, Hammer PM, Webber JD. Laparoscopic removal of a retained intra-abdominal ribbon malleable retractor after 14 years. J Laparoendosc Adv Surg Tech A 2006; 16:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26105/abstract/48\">",
"      Kaiser CW, Friedman S, Spurling KP, et al. The retained surgical sponge. Ann Surg 1996; 224:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26105/abstract/49\">",
"      Jackson, JZ. A primer on the unhappy defense of the surgeon in a retained sponge case. Med Law Update 2003; 3:10.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15699 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-217.117.136.88-94DAD92080-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_31_26105=[""].join("\n");
var outline_f25_31_26105=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H251480787\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H251480748\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H251480801\">",
"      RETAINED OBJECTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H251480808\">",
"      INCIDENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H251481323\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8420783\">",
"      NATIONAL MANDATE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H251482812\">",
"      PREVENTION STRATEGIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H251482826\">",
"      Care processes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H251482840\">",
"      - Standardized count protocols",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H93794279\">",
"      - Count discrepancies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H251482889\">",
"      - Radiographic screening",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H251482847\">",
"      Counting devices",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H251484200\">",
"      Cost",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H251482922\">",
"      Work environment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H251482854\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H251483055\">",
"      Exudative",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H251483062\">",
"      Fibrinous",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H251482861\">",
"      IMAGING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H733684518\">",
"      Plain film",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H733684662\">",
"      Gastrointestinal contrast studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H733684534\">",
"      Computed tomography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H733684541\">",
"      Other modalities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H251482868\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H251482875\">",
"      MEDICOLEGAL IMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H251480787\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/15699\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15699|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?30/25/31121\" title=\"diagnostic image 1\">",
"      Retained surgical sponge on plain abdominal film",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?15/18/15651\" title=\"diagnostic image 2\">",
"      Intraluminal retained surgical sponge",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?41/49/42769\" title=\"diagnostic image 3\">",
"      Retained surgical sponge of the liver on computed tomography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?40/10/41121\" title=\"diagnostic image 4\">",
"      Retained sponge of the breast on ultrasound",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?30/35/31285\" title=\"diagnostic image 5\">",
"      Retained surgical sponge on magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?19/20/19781\" title=\"diagnostic image 6\">",
"      Retained surgical sponge on FDG-PET",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/41/26264?source=related_link\">",
"      Negative pressure wound therapy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_31_26106="Procedures used for blood donor screening: Protection of potential blood donors and recipients";
var content_f25_31_26106=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Procedures used for blood donor screening: Protection of potential blood donors and recipients",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/31/26106/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/31/26106/contributors\">",
"     Steven Kleinman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/31/26106/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/31/26106/contributors\">",
"     Arthur J Silvergleid, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/31/26106/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/31/26106/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/31/26106/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 14, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H57715582\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A major goal of transfusion medicine practice has been to reduce the risk of transfusion-transmitted infection to as low a level as possible [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26106/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. In order to approach the desired level of zero risk from transfused allogeneic blood, multiple layers of safety are needed. Methods used in attempting to maximize safety from donated allogeneic units include donor selection criteria, donor medical history interview, the confidential unit exclusion (CUE) option, donor deferral registries, laboratory testing of donated units, donor initiated telephone call backs, and modification of the blood unit after collection, either by leukocyte removal or physicochemical procedures for pathogen inactivation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26106/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to assuring that the donated unit will not cause any adverse consequences for transfusion recipients, the evaluation of each prospective blood donor includes procedures to assure that the donor will not suffer any adverse reactions from the donation itself [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26106/abstract/5\">",
"     5",
"    </a>",
"    ], or from hematopoietic growth factors that may be employed to facilitate such donations [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26106/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Over the past three decades, procedures used to evaluate donors have changed dramatically. The increased awareness of potential spread of infectious disease by blood transfusion has resulted in much more elaborate donor screening for the purpose of protecting the transfusion recipient [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26106/abstract/5\">",
"     5",
"    </a>",
"    ]. At the same time, experience from autologous donation programs has lessened the concern about adverse donor reactions [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26106/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/54/12134?source=see_link\">",
"     \"Preoperative autologous blood donation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the last decade, standard serological testing of donated blood for Human Immunodeficiency Virus (HIV) and Hepatitis C Virus (HCV) has been supplemented by the addition of nucleic acid testing of pools of donations for HIV and HCV RNA, which allows for detection of additional infectious units [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26106/abstract/8\">",
"     8",
"    </a>",
"    ]. The current per unit risk estimate for acquiring HIV from transfusion is one in 1.5 to one in 2.1 million and for HCV is one in one million to one in two million [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26106/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prior to 2010, risks for Hepatitis B Virus (HBV) were estimated to range from one in 58,000 to one in 269,000. Since that time, as the result of additional donation testing, these risks are now estimated to range from one in 205,000 to one in 355,000 [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26106/abstract/9,11-13\">",
"     9,11-13",
"    </a>",
"    ]. Risk for human T-lymphotropic virus (HTLV) is estimated to be about one in two million when the older published risk estimate (one in 641,000) is adjusted for the fact that only one-third of potentially infectious units actually transmit HTLV infection, due to loss of viable virus upon blood component storage [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26106/abstract/12,14\">",
"     12,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This discussion will provide a general overview of the procedures involved in blood donor screening. Issues related to the blood donor medical history and the testing of donated blood are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/14/11498?source=see_link\">",
"     \"Blood donor medical history\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/41/40601?source=see_link\">",
"     \"Laboratory testing of donated blood\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ESTABLISHMENT OF PROCEDURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;When it is first suspected that an infectious agent may be transmitted by transfusion, the initial response is to develop donor deferral policies using epidemiologic data derived from high risk populations [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26106/abstract/3,5\">",
"     3,5",
"    </a>",
"    ]. After this initial step, subsequent review and debate often leads to the nationwide implementation of a particular donor screening procedure following recommendations of the Food and Drug Administration (FDA)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the AABB (formerly the American Association of Blood Banks) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26106/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. Once implemented, screening procedures tend to become permanent due to the current regulatory, political, and legal climate, even if their efficacy cannot be established.",
"   </p>",
"   <p>",
"    For many diseases, such as Creutzfeldt-Jacob disease (CJD), which has not been proven to be transfusion transmitted, variant CJD, babesiosis, and malaria, nonlaboratory donor screening procedures are the only method available for increasing transfusion safety [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26106/abstract/17-20\">",
"     17-20",
"    </a>",
"    ]. In contrast, for those infectious diseases for which routine blood donor testing is performed (HIV, HTLV, hepatitis C virus, hepatitis B virus, and syphilis), the importance of nonlaboratory donor screening procedures relates to their ability to identify some potentially infectious donors during the infectious, seronegative window period (",
"    <a class=\"graphic graphic_table graphicRef69661 \" href=\"UTD.htm?30/59/31676\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26106/abstract/2,12\">",
"     2,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While there are distinct advantages to eliminating donors with possible risks of disease transmission, there are also negative consequences of this approach [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26106/abstract/21\">",
"     21",
"    </a>",
"    ]. Because donor deferral criteria often have poor specificity, a large number of safe donors will be deferred [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26106/abstract/22\">",
"     22",
"    </a>",
"    ]. Although this dilemma has been well recognized, there is no available algorithm to decide if a given procedure or screening question should be implemented. Such decisions attempt to balance the following factors: the extent of disease transmission, the severity of the consequences of such disease to the recipient, the expected sensitivity (effectiveness) of the procedure, and the number of donors lost by implementation of the procedure. Deferral policies to protect against the theoretical risk of transfusion transmission of variant CJD have tended to choose potential recipient safety over blood availability. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/14/11498?source=see_link&amp;anchor=H17#H17\">",
"     \"Blood donor medical history\", section on 'Blood donor deferral'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     SPECIFIC DONOR SCREENING PROCEDURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Donor screening procedures can be conveniently divided into those that occur pre-donation, those that occur at the donation site, and those that occur after the blood unit has been collected but prior to its release for transfusion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Pre-donation screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pre-donation procedures include exclusion of collections at particular donor sites and elimination of donor incentives. Because of the known spread of hepatitis between individuals inhabiting particular types of institutions, blood collection agencies do not collect blood at homes for the mentally retarded or in prisons [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26106/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. In order to decrease the risk of HIV transmission, blood collection agencies do not collect from groups or institutions that are known to be comprised of male homosexuals [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26106/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The classic example of a donor incentive associated with disease transmission is the payment of cash in exchange for blood donation. Data collected in the 1970s showed higher rates of hepatitis B surface antigen (HBsAg) positivity in paid donors, higher rates of hepatitis B and non-A, non-B hepatitis in recipients of paid versus volunteer donor blood, and a substantial decrease in cases of posttransfusion hepatitis in transfusion recipients following elimination of commercial blood [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26106/abstract/26-28\">",
"     26-28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As a result of the risk associated with paid donors, the Food and Drug Administration instituted regulations in 1978 that required the labeling of a blood unit as either from a volunteer or a paid donor and several states passed legislation virtually prohibiting the use of commercial donor blood [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26106/abstract/29\">",
"     29",
"    </a>",
"    ]. The result has been the virtual elimination of paid donors from the whole blood collection system in the United States. Thus, volunteer donors are the source of the red cells, platelets, fresh frozen plasma and cryoprecipitate transfused to patients. In contrast, payment to plasmapheresis donors still occurs; these donors contribute units of plasma that are pooled together, subjected to viral inactivation techniques, and manufactured into plasma derivatives such as albumin, intravenous and intramuscular immunoglobulins, and factor VIII and IX concentrates.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Donor incentives",
"    </span>",
"    &nbsp;&mdash;&nbsp;Incentives other than the direct payment of cash (eg, time off from work, gifts, monetary credit for blood non- replacement fees, free cholesterol and PSA screening) also are used to encourage people to donate [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26106/abstract/30\">",
"     30",
"    </a>",
"    ]. Although there has been concern that such incentives may have an adverse influence on blood safety, several reports suggest that some incentives given to first time or repeat donors do not have an adverse effect on blood safety, as monitored by donor infectious disease testing results. However, these same data are lacking with regard to the influence of incentives on the safety profile of current non-donors who might be influenced to become donors by the incentives [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26106/abstract/31-35\">",
"     31-35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another incentive that appears to have motivated some people to donate blood is the ability to obtain a free and confidential HIV antibody test result as part of the process of blood donation. Post-donation interviews with HIV seropositive donors in the 1980s indicated that the motivation for donation in 15 to 29 percent was to obtain their HIV antibody test result [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26106/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. Furthermore, in an anonymous mail survey conducted in 1993, 6 percent of donors indicated that they had donated blood at some time in the past to obtain an HIV antibody test and 3.2 percent stated that they had done so within the past 12 months [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26106/abstract/38\">",
"     38",
"    </a>",
"    ]. In a similar survey conducted in 1998, the latter number decreased to 1.0 percent, with the majority of such donors indicating that they had done so for financial or convenience reasons [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26106/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    To address this issue, blood centers currently provide information to blood donors about the inappropriateness of HIV test seeking behavior. Some centers have adopted additional approaches such as specifically asking donors if they are donating to get an HIV test or offering free HIV testing to people who desire it without requiring that a blood donation be made. Despite these approaches, however, it appears that more effective ways are needed to educate prospective donors that donating to obtain HIV antibody test results may endanger transfusion recipients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Use of blood withdrawn for therapeutic purposes",
"    </span>",
"    &nbsp;&mdash;&nbsp;An additional donor incentive arises in the case of patients with disorders that require periodic phlebotomy, such as hereditary hemochromatosis (HH). From one point of view, donating blood may save a patient as much as 200 dollars per venesection [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26106/abstract/40\">",
"     40",
"    </a>",
"    ]. From another standpoint, a healthy person is available to REGULARLY donate as many as 50 units of whole blood per year. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/32/18952?source=see_link\">",
"     \"Treatment of hereditary hemochromatosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The FDA has adopted a policy that permits collection of blood from patients with hereditary hemochromatosis without any special unit labeling, provided that an individual blood center applies to the FDA for an exemption to the labeling rule. In order to qualify for this exemption, the blood center must perform therapeutic phlebotomies for hereditary hemochromatosis at no charge, hence removing the monetary incentive for a patient to be a donor, and must agree to collect data on viral markers and adverse reaction rates in these donors as well as data on adverse reactions in recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26106/abstract/41\">",
"     41",
"    </a>",
"    ]. Patients with hereditary hemochromatosis must still meet all other qualification criteria for allogeneic donation. Currently, there are many blood centers in the United States that will accept such donations.",
"   </p>",
"   <p>",
"    There are some data suggesting that donors with hereditary hemochromatosis are no less safe than other donors. In a large-scale anonymous mail survey of United States blood donors completed in 1998 before this policy change, the prevalence of unreported deferrable risks for transfusion-transmissible viral infections (TTVIs) was similar in patients with hemochromatosis (who donated inappropriately despite their diagnosis) and standard community allogeneic donors (2.0 and 3.1 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26106/abstract/42\">",
"     42",
"    </a>",
"    ]. The overall prevalence of positive screening test results for TTVIs was also similar (1.3 and 1.6 percent, respectively).",
"   </p>",
"   <p>",
"    Several studies have assessed the impact of collecting blood from donors with hereditary hemochromatosis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, 69 of 211 patients (33 percent) with hereditary hemochromatosis were ineligible as potential blood donors, and only 65 percent of the units obtained from potentially eligible donor-patients during the initial weekly (iron depletion stage) phlebotomy treatments were acceptable for transfusion [",
"      <a class=\"abstract\" href=\"UTD.htm?25/31/26106/abstract/43,44\">",
"       43,44",
"      </a>",
"      ]. However, this increased to 88 percent during the maintenance stage of therapy (ie, one to four phlebotomies per year).",
"     </li>",
"     <li>",
"      In a second series, 76 percent of 130 subjects with hereditary hemochromatosis met eligibility criteria for allogeneic donation. No incident seroconversions for agents of transfusion-transmissible disease occurred during 1,402 donations [",
"      <a class=\"abstract\" href=\"UTD.htm?25/31/26106/abstract/45\">",
"       45",
"      </a>",
"      ]. Twenty-seven months after starting the program, hemochromatosis donors were contributing 14 percent of the red cell units collected for allogeneic use at this small blood center. In addition, donors with hemochromatosis kept their donation appointments significantly more often than nonhemochromatosis donors (89 versus 75 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although these latter data suggest that collecting blood from patients with hemochromatosis is a promising way to increase overall red cell donations, such programs are not universally available in community blood centers because of the financial issues involved in offering free therapeutic phlebotomies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Screening at the donation site",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major procedure for screening donors at the donation site is the medical history interview which contains questions to protect the recipient from acquiring a transfusion transmitted infection and to protect the donor from suffering an adverse reaction after donation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/14/11498?source=see_link\">",
"     \"Blood donor medical history\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other donation site procedures include the opportunity for the donor to confidentially designate that the donated unit not be transfused, the use of a donor deferral registry, monitoring of the donor's vital signs (pulse, blood pressure, temperature) and determination of the adequacy of the donor's hemoglobin level [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26106/abstract/5,46\">",
"     5,46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Confidential unit exclusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;The procedure known as confidential unit exclusion (CUE) was introduced at many blood centers following a 1986 FDA recommendation stating that donors should be offered a procedure at the time of donation by which they could designate confidentially whether or not their blood should be transfused to others. The rationale for CUE was to provide an opportunity for those donors who felt pressured to donate (from peers, fellow employees, employers, etc) at a work place or community blood drive to indicate that their blood should not be transfused.",
"   </p>",
"   <p>",
"    The CUE procedure works as follows. After the donor interview but prior to donation of the unit, each blood donor indicates, usually through the use of computerized bar code stickers whether",
"    <span class=\"nowrap\">",
"     his/her",
"    </span>",
"    unit should or should not be used; if a donor neglects to make any indication, the unit will not be used.",
"   </p>",
"   <p>",
"    Two large studies have attempted to evaluate whether CUE is a useful procedure by analyzing whether donors who were shown to seroconvert for HIV used the CUE option on their preseroconversion sample [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26106/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. This is the most relevant group for evaluation of CUE's effect on transfusion safety since, unlike HIV seropositive units, these units would otherwise be transfused to recipients if the CUE procedure were not in place.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study of 322 HIV seroconverting donors at 40 blood centers, 3.4 percent of such preseroconversion donations were excluded; however, 9 of the 11 exclusions came from one center which has consistently shown results for the CUE procedure that differ from the remainder of the US [",
"      <a class=\"abstract\" href=\"UTD.htm?25/31/26106/abstract/47,49\">",
"       47,49",
"      </a>",
"      ]. If these data from the outlier blood center are eliminated, the data from the remaining 39 centers indicate that 0.8 percent (2 of 246) of HIV seroconverting donors used this option.",
"     </li>",
"     <li>",
"      In the second study evaluating 1.8 million donations at five blood centers, 6 percent (2 of 33) of HIV seroconverting donors used this option on their preseroconversion unit [",
"      <a class=\"abstract\" href=\"UTD.htm?25/31/26106/abstract/48\">",
"       48",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Given the very low rate of HIV transmission by transfusion and the low rate at which such seroconverting donors choose the CUE option, it has been estimated that this procedure may interdict one additional HIV infectious unit per 7.14 million blood donations. Despite the low efficacy for HIV transmission, donors who use CUE have higher rates of seropositivity for many infectious disease markers and some individuals who use CUE admit to HIV risk factors [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26106/abstract/47,48\">",
"     47,48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In 1992, the FDA analyzed the available data on CUE sensitivity and specificity and stated that the CUE procedure was no longer mandatory. At the current time, there are very few, if any, blood centers in the United States that use the CUE procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26106/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Registry of deferred donors",
"    </span>",
"    &nbsp;&mdash;&nbsp;An additional mechanism to protect recipients is the use of a registry of deferred donors [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26106/abstract/51\">",
"     51",
"    </a>",
"    ]. These registries are usually computerized, and include identifying information from donors who have been deferred for specified reasons. The donor deferral registry can be used in one of two ways. In most blood centers in recent years, the donor's name is checked against the deferral registry prior to donation; no blood is collected if the donor is listed on the registry. This method is highly desirable in that it avoids the unnecessary phlebotomy of ineligible donors and it prevents the potential for an error leading to the release of the ineligible donor unit. The alternate method of complying with the requirements for a donor deferral registry is to collect the unit from the donor and to subsequently, at a central location, check the donor deferral registry prior to placing the unit into inventory. The unit is quarantined and destroyed if the donor's name was found on the registry.",
"   </p>",
"   <p>",
"    Individual blood centers have established these in-house (local) donor deferral registries to comply with a section of the Code of Federal Regulations that states that persons who have ever tested positive for HBsAg or anti-HIV should no longer be accepted as blood donors. The rationale of donor deferral registries is that individuals with a previous positive test result may revert to a negative test result at a later date even though they could still transmit disease. This situation could occur either because of a biologic phenomenon or a testing error.",
"   </p>",
"   <p>",
"    Donor deferral registries also include the names of donors who have previously volunteered information (eg, history of intravenous drug use, hepatitis, or high risk AIDS activity) that should have permanently excluded them as blood donors. Donors who volunteer such information at one visit may be tempted to withhold this information at a subsequent visit, especially if their self-assessment is that the history ought not to have precluded them as blood donors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Effect of screening procedures on overall donor health",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary object of donor screening procedures is to insure the safety of the blood supply. As a result of these procedures, blood donors appear to reflect a healthy subset of the general population, as reflected by a lower mortality as well as a lower risk of cancer, cardiovascular disease, and transfusion-transmissible viral infection [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26106/abstract/52-56\">",
"     52-56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This premise was tested in a retrospective cohort study among over one million blood donors in Sweden and Denmark who were followed for up to 35 years following their first computer-registered blood donation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26106/abstract/56\">",
"     56",
"    </a>",
"    ]. Overall mortality and cancer incidence were 30 (95% CI 29-31) and 4 (95% CI 2-5) percent lower than the general population. In addition, there was a trend towards lower mortality relative to the general population among blood donors who started donating more recently, when donor screening procedures became increasingly more stringent. The same pattern existed for all causes of death, but was most pronounced for infectious diseases and diseases of the respiratory or cardiovascular system.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     POSTDONATION SCREENING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary post-donation procedure for enhancing recipient safety is laboratory testing of the donated unit for multiple infectious disease markers. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/41/40601?source=see_link\">",
"     \"Laboratory testing of donated blood\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A second safety procedure is the telephone callback. At the time of blood donation, donors receive instructions that they may call the blood center sometime after the donation to report additional pertinent medical history information. Telephone callbacks fall into two prominent categories.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Donors may call back to report the development of an acute illness such as fever, upper respiratory tract infection, or a gastrointestinal disorder occurring from several hours to several days post-donation.",
"     </li>",
"     <li>",
"      Donors may call back to indicate risk factors for HIV or other infectious diseases that might not have been disclosed at the time of donation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Blood centers must have established policies for managing post-donation telephone callback information. In general, if post-donation information would have caused the donor to be deferred, blood centers will quarantine and destroy any components that have not yet been shipped and will transmit such information, usually by letter, to the hospital transfusion services that have received components from the donation. The transfusion service will retrieve any such components that are still in their inventory and either return them to the blood center or destroy them.",
"   </p>",
"   <p>",
"    Post-donation information that affects the eligibility evaluation of the donor must be reported by licensed blood establishments to the FDA. In the FDA's summary of blood product deviation reports for fiscal year 2007, there were 30,033 reports of post donation information (obtained either via telephone callback or at a subsequent donation) that led to a reassessment of donor eligibility. This constituted 70 percent of the total blood product deviations reported that year [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26106/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     PROTECTION OF THE DONOR AND DEFERRAL CRITERIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Deferral criteria for the protection of the donor are based upon establishing that the donor does not fall into a group that is likely to have an increased risk of immediate post-donation reactions or a post-donation reaction that is especially severe or prolonged or for which his cardiovascular status does not permit him to adequately compensate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     General requirements",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H110596221\">",
"    <span class=\"h3\">",
"     Estimated blood volume",
"    </span>",
"    &nbsp;&mdash;&nbsp;To reduce the risk of acute hypovolemic reactions, most blood centers defer donors who weigh less than 50 kg; at this weight, the estimated blood volume for an adult is 3500 mL and phlebotomy of 525 mL of blood (ie, 500 mL collection plus 25 mL sample volume) results in a 15 percent reduction in the donor's blood volume [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26106/abstract/58\">",
"     58",
"    </a>",
"    ]. Not surprisingly, the rate of donor reactions has been demonstrated to be inversely proportional to body weight, with the highest reaction rates in donors weighing between 50 and 54 kg [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26106/abstract/59\">",
"     59",
"    </a>",
"    ]. In a report of 11,333 apheresis collections, moderate to severe acute adverse events (AAEs) were seen in 0.47 percent; small, female donors with lower pre-donation hematocrits were at significantly higher risk for such AAEs [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26106/abstract/60\">",
"     60",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/14/11498?source=see_link&amp;anchor=H24#H24\">",
"     \"Blood donor medical history\", section on 'Protection of the donor'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Since 2009, all American Red Cross regional blood centers implemented a new selection criterion for 16- to 18-year-old donors, based upon the donor&rsquo;s sex and self-reported height and weight. This requires donors to have an estimated blood volume of at least 3.5 liters, using the following equations (blood volume in liters, height in meters, weight in kilograms) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26106/abstract/61\">",
"     61",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Blood volume (males) &nbsp;= (0.3669) x (height)",
"    <sup>",
"     3",
"    </sup>",
"    + (0.03219) x (weight) &nbsp;+ 0.6041",
"    <br/>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Blood volume (females) &nbsp;= (0.3561) x (height)",
"    <sup>",
"     3",
"    </sup>",
"    + (0.03308) x (weight) &nbsp;+ 0.1833",
"   </p>",
"   <p>",
"    This safety initiative has led to decreasing complications among donors aged 16 to 18, such that the risk of a presyncopal or syncopal reaction for 16-year-olds is no longer different from that observed for 19-year-olds in an analysis stratified by age, sex, and donation status.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H110596228\">",
"    <span class=\"h3\">",
"     Other requirements",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other indications for deferral of the donor include temperature above 37.5&ordm;C, blood pressure above 180 systolic or 100 diastolic, pulse rate outside the established limits of 50 to 100 beats per minute, and an arrhythmia detected on pulse examination. Exceptions may be made upon the discretion of the medical director. One common exception is for athletes in whom lower pulse rates are an indication of enhanced cardiovascular conditioning.",
"   </p>",
"   <p>",
"    Individuals can donate blood from age 16 onward in most of the United States, though some states have a lower age limit of 17 years [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26106/abstract/62\">",
"     62",
"    </a>",
"    ]. In virtually all states that allow 16 year olds to donate, written permission is required for those between 16 and 17. There is no upper age limit for blood donation in the United States; some countries do have an upper age limit.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Detection of anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;A donor hemoglobin concentration is determined prior to donation to assure that the donor does not have preexisting anemia, that the donor will not be made anemic by the blood donation, and to ensure an adequate therapeutic dose of red cells (and hemoglobin) in the collected unit [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26106/abstract/5,63,64\">",
"     5,63,64",
"    </a>",
"    ]. The acceptable minimal hemoglobin level for blood donation in the United States is 12.5",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    for both males and females, as mandated by FDA requirements [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26106/abstract/16,65\">",
"     16,65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the past, the hemoglobin determination was made on capillary samples obtained either by earstick or fingerstick. However, data showing that the earstick hemoglobin value can be erroneously high has led to more standardized policies of assessing donor hemoglobin from a fingerstick sample [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26106/abstract/64,66,67\">",
"     64,66,67",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Repeat blood donors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blood donors may donate one unit of whole blood at a frequency of every 56 days, a time interval sufficient for most donors to recover their pre-donation hemoglobin mass [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26106/abstract/68\">",
"     68",
"    </a>",
"    ]. However, some donors are unable to maintain their hematocrit at acceptable levels with this donation frequency; furthermore, many adults donating at this frequency (ie, \"superdonors\") become iron deficient as evidenced by low serum ferritin levels [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26106/abstract/69-73\">",
"     69-73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Use of oral iron supplements (eg, 20 to 40 mg of elemental iron PO per day) may allow an additional group of donors to meet these hematocrit requirements and donate at the maximum allowable frequency (ie, six times per year for men and four times per year for women in certain countries) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26106/abstract/74-76\">",
"     74-76",
"    </a>",
"    ]. Although the use of oral iron supplements to allow more frequent blood donation is not standard practice in many countries, including the United States, arguments have been made in favor of such supplementation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26106/abstract/73,77,78\">",
"     73,77,78",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Apheresis red cell donors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Automated apheresis technology permits the collection of",
"    <strong>",
"     double",
"    </strong>",
"    red cell units in one sitting (erythrocyte apheresis) with safety, especially in young donors [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26106/abstract/79\">",
"     79",
"    </a>",
"    ]. In the United States, donors are required to wait at least 16 weeks between such collections. In one series, double unit donors not receiving iron supplementation reestablished their baseline hematocrit at two months post-phlebotomy, but their serum ferritin levels, although still within the normal range, were one-half that of pre-donation levels [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26106/abstract/80\">",
"     80",
"    </a>",
"    ]. In some subjects, serum ferritin did not return to normal by four months post-phlebotomy.",
"   </p>",
"   <p>",
"    Use of oral iron supplements can repair the deficit in serum ferritin [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26106/abstract/81\">",
"     81",
"    </a>",
"    ]. Such supplementation might allow more United States donors to qualify for repeat double unit donation every 16 weeks, and, in countries where iron supplementation and more frequent donation are permitted, might allow collection of two red cell units as often as every 8 to 10 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26106/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Serum ferritin, iron and red cell indices, and HFE mutational status have been suggested as tools to monitor iron stores in these donors, as well as in females who donate whole blood frequently [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26106/abstract/82-84\">",
"     82-84",
"    </a>",
"    ]. Specifically, ferritin measurement has not been found to be practical or economical enough to implement in the context of routine blood donor screening. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/39/26234?source=see_link&amp;anchor=H26#H26\">",
"     \"Causes and diagnosis of anemia due to iron deficiency\", section on 'Serum or plasma ferritin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Apheresis platelet donors",
"    </span>",
"    &nbsp;&mdash;&nbsp;In an effort to reduce the risk of thrombocytopenia and loss of \"thrombopoietic reserve\" [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26106/abstract/85,86\">",
"     85,86",
"    </a>",
"    ], current FDA regulations limit platelet apheresis donations to 24 donations in a 12-month period. As an example of this potential problem, long-term regular plateletpheresis donation was shown to cause a decrease in the platelet count of donors proportional to the cumulative number of donations [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26106/abstract/87\">",
"     87",
"    </a>",
"    ]. The maximum fall averaged",
"    <span class=\"nowrap\">",
"     29,000/microL",
"    </span>",
"    in those with 21 to 30 donations in a four-year period. However, deferral of donors for low platelet counts (temporary:",
"    <span class=\"nowrap\">",
"     &lt;150,000/microL;",
"    </span>",
"    permanent:",
"    <span class=\"nowrap\">",
"     &lt;100,000/microL)",
"    </span>",
"    was infrequent, occurring at a rate of only 2 percent per year. Of the eight donors who were permanently deferred from further platelet donations, three were found to have an underlying hematologic disorder.",
"   </p>",
"   <p>",
"    That the current FDA regulations are overly restrictive was suggested by a single center study of 60 donors who had provided 24 platelet donations during calendar year 2005. There was no clinically or statistically significant difference in mean platelet counts from the first through the 24th donation; none of these 60 repeat donors was deferred, even once, for a platelet count",
"    <span class=\"nowrap\">",
"     &lt;150,000/microL",
"    </span>",
"    during this period [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26106/abstract/88\">",
"     88",
"    </a>",
"    ]. In a similar study of 471 repeat apheresis platelet donors followed over 2.5 years, the platelet count actually increased slightly for each platelet product donated, and no deferrals due to a platelet count",
"    <span class=\"nowrap\">",
"     &lt;150,000/microL",
"    </span>",
"    occurred [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26106/abstract/89\">",
"     89",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Citrate toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;During the course of a standard plateletpheresis procedure, a donor may receive up to 10 grams (53 mmol) of citrate intravenously over 90 to 120 minutes [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26106/abstract/90\">",
"     90",
"    </a>",
"    ]. This may be associated with significant decreases in serum ionized calcium, magnesium, and phosphate [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26106/abstract/91\">",
"     91",
"    </a>",
"    ], and prolongation of the QT interval [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26106/abstract/92\">",
"     92",
"    </a>",
"    ], often associated with symptoms such as paresthesias, muscle cramping, and nausea. In a study of over 19,000 apheresis procedures, 0.8 percent were associated with adverse events, of which 70 involved hemodynamic or citrate-related complications [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26106/abstract/93\">",
"     93",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/31/6646?source=see_link&amp;anchor=H5#H5\">",
"     \"Complications of therapeutic plasma exchange\", section on 'Citrate-induced hypocalcemia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/50/36646?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical manifestations of hypocalcemia\", section on 'Acute manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The usual treatment for symptoms related to hypocalcemia is to decrease the rate of infusion of citrate, to give oral calcium-containing agents, or both [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26106/abstract/94\">",
"     94",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Citrate toxicity may be more severe in subjects undergoing peripheral blood progenitor cell donation, due to the longer durations required to process the required volume of blood [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26106/abstract/95-97\">",
"     95-97",
"    </a>",
"    ]. Ionized calcium and magnesium levels may fall by as much as 35 and 56 percent, respectively, and may remain depressed for 24 hours after the procedure. In two studies, prophylactic infusion of calcium solutions reduced clinically significant symptoms by 65 to 96 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26106/abstract/95,97\">",
"     95,97",
"    </a>",
"    ]. There was no evidence of blood coagulation in the apheresis device or in the apheresis component in procedures performed with calcium infusion, provided infusions were stopped during pauses in blood processing, and no interference with the number of CD34+ cells collected.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Stimulation of thrombopoiesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of substances with thrombopoietic activity to increase platelet counts in normal donors, and thus increase platelet yields from apheresis has been evaluated.",
"   </p>",
"   <p>",
"    A trial has been reported in which 59 normal platelet donors were randomly assigned to receive either placebo or a single injection of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) at two different doses (1 or 3",
"    <span class=\"nowrap\">",
"     &micro;g/kg)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26106/abstract/98\">",
"     98",
"    </a>",
"    ]. Placebo-treated donors provided a mean of 3.8 x 10",
"    <sup>",
"     11",
"    </sup>",
"    platelets, while PEG-rHuMGDF- treated donors provided 5.6 and 11.0 x 10",
"    <sup>",
"     11",
"    </sup>",
"    platelets at the lower and higher doses, respectively. The frequency of substandard collections (ie, &lt;3 x 10",
"    <sup>",
"     11",
"    </sup>",
"    platelets collected) was 26, 4, and zero percent in the placebo- and the low- and high-dose treatment groups, respectively. There were no serious adverse events or dose-limiting toxicities reported; none of the donors developed antibodies.",
"   </p>",
"   <p>",
"    Platelets obtained from the above study were transfused into patients with platelet counts",
"    <span class=\"nowrap\">",
"     &le;25,000/&micro;L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26106/abstract/99\">",
"     99",
"    </a>",
"    ]. Platelets obtained from donors treated with PEG-rHuMGDF were clinically safe, and resulted in significantly greater platelet count increments and longer transfusion-free intervals than those obtained from placebo-treated donors.",
"   </p>",
"   <p>",
"    Unfortunately, the use of PEG-rHuMGDF in normal donors has been hampered by the production of antibodies in a small percent of donors receiving more than one dose. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/61/21466?source=see_link&amp;anchor=H33#H33\">",
"     \"Clinical applications of thrombopoietic growth factors\", section on 'Antibody formation'",
"    </a>",
"    .) Accordingly, further development of PEG-rHuMGDF has been stopped.",
"   </p>",
"   <p>",
"    In a second study, patients with gynecologic malignancies scheduled to receive chemotherapy underwent treatment with two doses of recombinant human thrombopoietin (full-length glycosylated molecule, Genentech, South San Francisco) at a dose of 1.2",
"    <span class=\"nowrap\">",
"     &micro;g/kg",
"    </span>",
"    IV on days one and four, followed by up to four platelet phereses starting on day 12, until a target of 50 units of platelets had been collected [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26106/abstract/100\">",
"     100",
"    </a>",
"    ]. No patient developed neutralizing antibodies to thrombopoietin; side effects were confined to those associated with hypocalcemia (see",
"    <a class=\"local\" href=\"#H18\">",
"     'Citrate toxicity'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    As an integral part of the study, the collected platelets were cryopreserved and used for autologous transfusion when platelet counts fell to",
"    <span class=\"nowrap\">",
"     &lt;15,000/microL",
"    </span>",
"    following chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26106/abstract/100\">",
"     100",
"    </a>",
"    ]. These autologous platelet transfusions produced no transfusion reactions other than transient mild alterations in taste and smell during transfusion in two subjects, likely due to residual amounts of the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/22/33123?source=see_link\">",
"     dimethylsulfoxide",
"    </a>",
"    cryopreservative.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Apheresis granulocyte donors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Donors of granulocytes may be given",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/13/23767?source=see_link\">",
"     granulocyte colony-stimulating factor",
"    </a>",
"    (G-CSF) on the day prior to the pheresis procedure in order to increase the yield of harvested granulocytes. A history of hypertension, diabetes, gastrointestinal ulcers, glaucoma, tuberculosis, or any fungal infections may be contraindications to steroid administration.",
"   </p>",
"   <p>",
"    Side effects associated with the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    , G-CSF, or both are common but usually minor, and include headache, arthralgias, bone pain, fatigue, insomnia, and headache. Allergic reactions have been documented, as has fever. Long-term safety issues involved with dosing normal persons have not yet been definitively answered but the estimated risk is very low. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/18/4393?source=see_link&amp;anchor=H10#H10\">",
"     \"Granulocyte transfusions\", section on 'Donor issues'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     COMPLICATIONS OF BLOOD DONATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;In an effort to determine the overall incidence of adverse events occurring within days to weeks following phlebotomy, 1000 randomly selected whole blood donors were interviewed by telephone approximately three weeks following donation of one unit of whole blood [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26106/abstract/101\">",
"     101",
"    </a>",
"    ]. Thirty-six percent of donors reported one or more adverse effects; these were significantly more common in women than men (48 versus 23 percent) and in first-time donors as compared with repeat donors (47 versus 36 percent). The most common adverse events and their incidences were:",
"   </p>",
"   <p>",
"    Local reactions at the phlebotomy site:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Bruise at the needle site &mdash; 23 percent",
"     </li>",
"     <li>",
"      Sore arm &mdash; 10 percent",
"     </li>",
"     <li>",
"      Hematoma at needle site &mdash; 2 percent",
"     </li>",
"     <li>",
"      Sensory changes in the arm used for donation (eg, burning pain, numbness, tingling) &mdash; 1 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Systemic reactions:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fatigue &mdash; 8 percent",
"     </li>",
"     <li>",
"      Vasovagal symptoms &mdash; 5 percent",
"     </li>",
"     <li>",
"      Nausea and vomiting &mdash; 1 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Notably, none of these events was severe enough to require medical attention. While the local reactions at the phlebotomy site were almost certainly a consequence of the blood donation, the delayed interviewing format of the study made it less certain that the systemic symptoms were related to the blood donation. Therefore, other studies (see below) provide more reliable and detailed information on vasovagal reactions.",
"   </p>",
"   <p>",
"    A more definitive estimate of the risks of blood donation was undertaken by the American Red Cross, starting in 2003. Complications rates in 2006 were as follows for the following procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26106/abstract/102\">",
"     102",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Whole blood donation &mdash;",
"      <span class=\"nowrap\">",
"       350/100,000",
"      </span>",
"      donations",
"     </li>",
"     <li>",
"      Apheresis platelet collection &mdash;",
"      <span class=\"nowrap\">",
"       580/100,000",
"      </span>",
"      donations",
"     </li>",
"     <li>",
"      Automated red cell collection &mdash;",
"      <span class=\"nowrap\">",
"       540/100,000",
"      </span>",
"      donations",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The vast majority of these were presyncopal reactions and small hematomas. Excluding large hematomas, the overall rate of major complications for the three above procedures were 7.4, 5.2, and 3.3 per 10,000 donations, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Vasovagal syncope",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vasovagal reactions, especially those accompanied by syncope, have been the main focus of blood donor safety issues and occur in approximately 2 to 5 percent of blood donors [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26106/abstract/101,103-105\">",
"     101,103-105",
"    </a>",
"    ]. In a retrospective case control study from three large United States blood centers, involving 1890 blood donors with syncope, the most significant adverse risk factors for development of syncope were, in descending order, younger age, lower body weight, and first time donation status [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26106/abstract/106\">",
"     106",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A second study evaluated this problem during a one-year observation period in an urban blood center, comprising 194,000 donations. There were 178 reported cases of syncope, for an incidence of 0.09 percent. The following observations were made [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26106/abstract/107\">",
"     107",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When compared with the general donor population, those with syncopal reactions were more likely to be younger (28 versus 42 years) and first-time donors (35 versus 14 percent). Women had 49 percent more syncopal reactions than men.",
"     </li>",
"     <li>",
"      Syncope occurred before, during (or immediately after) donation, at the refreshment table, or off site in 1, 26, 61, and 12 percent of cases, respectively.",
"     </li>",
"     <li>",
"      Of the 19 evaluable offsite reactions, 84 and 100 percent occurred within one or three hours of leaving the donation site, respectively.",
"     </li>",
"     <li>",
"      Overall, 25 of the 178 donors with syncope (14 percent) sustained a traumatic injury, five of which required emergency department consultation; no hospital admissions were required, and there was only one long-term complication. Sixty percent of the injuries occurred in the refreshment area.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a study of 1459 donors from high school (HS) blood drives, the incidence of vasovagal reactions was significantly higher in Caucasian than in African-American HS students (8.2 versus 1.3 percent, relative risk 6.2, 95 percent confidence interval: 2.0 to 19) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26106/abstract/108\">",
"     108",
"    </a>",
"    ]. The reason(s) for this difference were not studied by the investigators, but did not appear to be due to differences in donor body weight [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26106/abstract/109\">",
"     109",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among Caucasian HS donors, the relative risks for vasovagal reaction were 2.6, 4.1, and 5.0 for first-time donors, weight &le;130 pounds, and a combination of the two, respectively. Reactions were significantly more common in females than males overall (11.3 versus 4.8 percent); rates were similar when donors weighing &lt;150 pounds were excluded from analysis (5.7 versus 4.6 percent).",
"   </p>",
"   <p>",
"    Similar results were obtained from a 2006 prospective study from nine American Red Cross blood centers that routinely collect blood from 16- to 19-year-olds, a population that now accounts for 14.5 percent of annual donations. Results included [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26106/abstract/110\">",
"     110",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Complications (eg, loss of consciousness, presyncope, hematoma, nerve irritation, arterial puncture) occurred in 10.7, 8.3, and 2.8 percent of donations from those who were 16 to 17, 18 to 19, or &gt;20 years of age, respectively. On multivariate analysis, young age (odds ratio 3.0), first time donation status (OR 2.6), and female sex (OR 1.9) had the strongest association with complications.",
"     </li>",
"     <li>",
"      The rates of physical injury from syncope-related falls were significantly greater in the youngest donors, and were 5.9, 2.4, and 0.4 (events per 10,000 collections) in donors who were 16 to 17, 18 to 19, or &gt;20 years of age, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given that, in the study cited above, most reactions occurred either immediately after donation or at the refreshment table, it would seem most prudent to make sure the donor feels well before being allowed to walk to the refreshment table and is encouraged to stay at the table for at least 10 to 15 minutes for observation and fluid replenishment. A further recommendation would be to have the donor sit in a forward leaning position with elbows and forearms on the table and feet flat on the floor [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26106/abstract/107\">",
"     107",
"    </a>",
"    ]. Should syncope occur, the donor would be more likely fall forward onto the table, rather than sideways towards the floor.",
"   </p>",
"   <p>",
"    Donors who develop presyncope or syncope should assume the supine position with legs raised or Trendelenburg position at the onset of such symptoms. Some may require smelling salts (ie,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/60/39873?source=see_link\">",
"     aromatic ammonia spirit",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prevention of adverse reactions may be especially necessary in younger donors, who are more likely to develop an adverse reaction to blood donation (see above) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26106/abstract/105\">",
"     105",
"    </a>",
"    ]. As an example, in one study 16-year-old donors who experienced even a minor complication were significantly less likely to return to donate within 12 months than 16-year-olds who experienced uncomplicated donations (52 versus 73 percent, respectively; odds ratio 0.40; 95% CI 0.36-0.44) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26106/abstract/110\">",
"     110",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A small randomized trial testing the ability of pre-donation water ingestion to attenuate negative reactions to blood donation was performed in 83 first-time blood donors recruited from a population of college undergraduate students [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26106/abstract/111\">",
"     111",
"    </a>",
"    ]. Participants assigned to ingest 500 mL of bottled water 30 minutes before donation had a 47 percent reduction of mild donation reaction symptoms (eg, dizziness, lightheadedness) when compared with the group not ingesting water pre-donation. The benefit of water ingestion did not vary as a function of the donors' existing hydration level, as measured by bioimpedance analysis.",
"   </p>",
"   <p>",
"    A similar, but not randomized, trial noted that vasovagal reactions (VVR) were common (6 of 31, 19 percent) in a small number of subjects who had heart rate increases &ge;15",
"    <span class=\"nowrap\">",
"     beats/minute",
"    </span>",
"    during 5 minutes of standing either before or after blood donation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26106/abstract/112\">",
"     112",
"    </a>",
"    ]. In the second part of this study, 46 of these \"high-risk\" donors ingested 300 mL of water 15 minutes before blood donation. This maneuver significantly reduced their heart rate increase after standing, and resulted in a lower incidence of VVR (2 of 45, 4 percent).",
"   </p>",
"   <p>",
"    A larger trial, involving 8894 donations from high school students, indicated a 21 to 28 percent reduction in the donor vasovagal reaction rate in those randomly assigned to receive a 473 mL (16 ounces) water drink before their donation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26106/abstract/113\">",
"     113",
"    </a>",
"    ]. The main benefit was seen in Caucasian first-time donors.",
"   </p>",
"   <p>",
"    A retrospective observational cohort study compared the vasovagal reaction rates for a 12-month period before and after implementation of a three-part intervention to reduce reactions. These included the following [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26106/abstract/114\">",
"     114",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Restricting donation to less than 15 percent of a donor&rsquo;s estimated blood volume for younger donors (ie, not accepting blood donations from donors &lt;23 years of age who had an estimated blood volume &lt;3500 mL) (see",
"      <a class=\"local\" href=\"#H110596221\">",
"       'Estimated blood volume'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Encouraging applied muscle tension during donation",
"     </li>",
"     <li>",
"      Providing approximately 500 mL of water before donation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The combined interventions significantly decreased the aggregate hypotensive (eg, presyncopal and syncopal) reaction rates in males and females by 24 percent, with a 25 percent decrease in delayed reactions (defined as more than four minutes after the conclusion of the phlebotomy, at which time the donor has stood up) and a 38 percent decrease in off-site reactions in female donors.",
"   </p>",
"   <p>",
"    Provision of a supportive individual during the donation, especially for relatively novice donors, may enhance the donation experience and increase donor retention [",
"    <a class=\"abstract\" href=\"UTD.htm?25/31/26106/abstract/115\">",
"     115",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?21/52/22338?source=see_link\">",
"       \"Patient information: Blood donation (giving blood) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?26/12/26820?source=see_link\">",
"       \"Patient information: Blood donation and transfusion (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12093587\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Methods used to maximize safety of allogeneic blood transfusion include those for protection of the recipient as well as protection of the donor.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Recipient protection",
"      </strong>",
"       These include donor selection criteria, medical history interview, donor deferral registries, laboratory testing of donated units, donor initiated telephone call backs, and modification of the blood unit after collection, either by leukocyte removal or physicochemical procedures for pathogen inactivation. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Specific donor screening procedures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Donor protection",
"      </strong>",
"       Donor deferral criteria are based on determining that the donation will not adversely affect the donor&rsquo;s health. Indications for deferral of the donor include a hemoglobin less than 12.5",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      for both men and women, temperature above 37.5&ordm;C, blood pressure above 180 systolic or 100 diastolic, pulse outside the established limits of 50 to 100",
"      <span class=\"nowrap\">",
"       beats/minute,",
"      </span>",
"      certain arrhythmias detected on pulse examination, and a variety of medical conditions. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Protection of the donor and deferral criteria'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Minimizing post-donation vaso-vagal reactions",
"      </strong>",
"       Post-donation reactions can be minimized by restricting donation to less than 15 percent of a donor&rsquo;s estimated blood volume (for younger donors, estimated blood volume must be &gt;3500 mL in order to be accepted for donation), encouraging applied muscle tension during donation, providing approximately 500 mL of water before donation, making sure the donor feels well before being allowed to walk to the refreshment table, and encouraging the donor to stay at the table for at least 10 to 15 minutes for observation and fluid replenishment. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Vasovagal syncope'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26106/abstract/1\">",
"      AuBuchon JP, Birkmeyer JD, Busch MP. Safety of the blood supply in the United States: opportunities and controversies. Ann Intern Med 1997; 127:904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26106/abstract/2\">",
"      McCullough J. The nation's changing blood supply system. JAMA 1993; 269:2239.",
"     </a>",
"    </li>",
"    <li>",
"     Kleinman S. Donor selection and screening procedures. In: Safety Current Challenges, Nance SJ (Ed), American Association of Blood Banks, Bethesda, MD 1992. p.169.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26106/abstract/4\">",
"      Goodnough LT, Shander A, Brecher ME. Transfusion medicine: looking to the future. Lancet 2003; 361:161.",
"     </a>",
"    </li>",
"    <li>",
"     Kleinman S. Donor Screening Procedures. In: Practice of Transfusion Medicine, 3rd ed, Petz L, Swisher S, Kleinman S, et al (Eds), Churchill-Livingstone, New York 1996. p.245.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26106/abstract/6\">",
"      McCullough J, Kahn J, Adamson J, et al. Hematopoietic growth factors--use in normal blood and stem cell donors: clinical and ethical issues. Transfusion 2008; 48:2008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26106/abstract/7\">",
"      Goldfinger D, Capon S, Czer L, et al. Safety and efficacy of preoperative donation of blood for autologous use by patients with end-stage heart or lung disease who are awaiting organ transplantation. Transfusion 1993; 33:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26106/abstract/8\">",
"      Stramer SL, Caglioti S, Strong DM. NAT of the United States and Canadian blood supply. Transfusion 2000; 40:1165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26106/abstract/9\">",
"      Dodd RY, Notari EP 4th, Stramer SL. Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population. Transfusion 2002; 42:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26106/abstract/10\">",
"      Zou S, Dorsey KA, Notari EP, et al. Prevalence, incidence, and residual risk of human immunodeficiency virus and hepatitis C virus infections among United States blood donors since the introduction of nucleic acid testing. Transfusion 2010; 50:1495.",
"     </a>",
"    </li>",
"    <li>",
"     Glynn S. Residual risks for hepatitis and HIV and unreported deferrable risk in US blood donors. Canadian Blood Services Consensus Conference Proceedings: \"Blood-borne HIV and Hepatitis: optimizing the donor selection process\". Ottawa, Ontario, Canada, November 7-9, 2001.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26106/abstract/12\">",
"      Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ. The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study. N Engl J Med 1996; 334:1685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26106/abstract/13\">",
"      Zou S, Stramer SL, Notari EP, et al. Current incidence and residual risk of hepatitis B infection among blood donors in the United States. Transfusion 2009; 49:1609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26106/abstract/14\">",
"      Donegan E, Lee H, Operskalski EA, et al. Transfusion transmission of retroviruses: human T-lymphotropic virus types I and II compared with human immunodeficiency virus type 1. Transfusion 1994; 34:478.",
"     </a>",
"    </li>",
"    <li>",
"     Standards for blood banks and transfusion services, 18th ed, Price TH (Ed), American Association of Blood Banks, Bethesda, MD 2008.",
"    </li>",
"    <li>",
"     US Department of Health and Human Services, Food and Drug Administration. The code of federal regulations, Washington, DC: US Government Printing Office, 2008 (revised annually).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26106/abstract/17\">",
"      Ricketts MN, Cashman NR, Stratton EE, ElSaadany S. Is Creutzfeldt-Jakob disease transmitted in blood? Emerg Infect Dis 1997; 3:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26106/abstract/18\">",
"      Appleman MD, Shulman IA, Saxena S, Kirchhoff LV. Use of a questionnaire to identify potential blood donors at risk for infection with Trypanosoma cruzi. Transfusion 1993; 33:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26106/abstract/19\">",
"      Gerber MA, Shapiro ED, Krause PJ, et al. The risk of acquiring Lyme disease or babesiosis from a blood transfusion. J Infect Dis 1994; 170:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26106/abstract/20\">",
"      Nahlen BL, Lobel HO, Cannon SE, Campbell CC. Reassessment of blood donor selection criteria for United States travelers to malarious areas. Transfusion 1991; 31:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26106/abstract/21\">",
"      Whittaker S, Carter N, Arnold E, et al. Understanding the meaning of permanent deferral for blood donors. Transfusion 2008; 48:64.",
"     </a>",
"    </li>",
"    <li>",
"     Kaplan HS, Kleinman SH. AIDS: blood donor studies and screening methods. In: Infection, Immunity and Blood Transfusion, Barker LF, Dodd RY (Eds), Alan R Liss, New York 1985. p.297.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26106/abstract/23\">",
"      SCHAFER IA, MOSLEY JW. A study of viral hepatitis in a penal institution. Ann Intern Med 1958; 49:1162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26106/abstract/24\">",
"      Krugman S, Friedman H, Lattimer C. Hepatitis A and B: serologic survey of various population groups. Am J Med Sci 1978; 275:249.",
"     </a>",
"    </li>",
"    <li>",
"     American Association of Blood Banks, American Red Cross, Council of Community Blood Centers: Joint statement on acquired immune deficiency syndrome related to transfusion. January 13, 1983.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26106/abstract/26\">",
"      Cherubin CE, Prince AM. Serum hepatitis specific antigen (SH) in commercial and volunteer sources of blood. Transfusion 1971; 11:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26106/abstract/27\">",
"      Szmuness W, Prince AM, Brotman B, Hirsch RL. Hepatitis B antigen and antibody in blood donors: an epidemiologic study. J Infect Dis 1973; 127:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26106/abstract/28\">",
"      Alter HJ, Holland PV, Purcell RH, et al. Posttransfusion hepatitis after exclusion of commercial and hepatitis-B antigen-positive donors. Ann Intern Med 1972; 77:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26106/abstract/29\">",
"      Barker LF. International forum: Which criteria must be fulfilled for a donation or a donor to be considered voluntary. Vox Sang 1978; 34:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26106/abstract/30\">",
"      Glynn SA, Williams AE, Nass CC, et al. Attitudes toward blood donation incentives in the United States: implications for donor recruitment. Transfusion 2003; 43:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26106/abstract/31\">",
"      Mayo DJ. Evaluating donor recruitment strategies. Transfusion 1992; 32:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26106/abstract/32\">",
"      Sanchez AM, Ameti DI, Schreiber GB, et al. The potential impact of incentives on future blood donation behavior. Transfusion 2001; 41:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26106/abstract/33\">",
"      Strauss RG. Blood donations, safety, and incentives. Transfusion 2001; 41:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26106/abstract/34\">",
"      Glynn SA, Smith JW, Schreiber GB, et al. Repeat whole-blood and plateletpheresis donors:unreported deferrable risks, reactive screening tests, andresponse to incentive programs. Transfusion 2001; 41:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26106/abstract/35\">",
"      Williams AE, Glynn SA, Bethel J, Ameti DI. Blood donation incentives: attitudes and risk relationships among first time and repeat whole blood donors (abstract). Transfusion 2000; 40:1S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26106/abstract/36\">",
"      Doll LS, Petersen LR, White CR, Ward JW. Human immunodeficiency virus type 1-infected blood donors: behavioral characteristics and reasons for donation. The HIV Blood Donor Study Group. Transfusion 1991; 31:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26106/abstract/37\">",
"      Leitman SF, Klein HG, Melpolder JJ, et al. Clinical implications of positive tests for antibodies to human immunodeficiency virus type 1 in asymptomatic blood donors. N Engl J Med 1989; 321:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26106/abstract/38\">",
"      Williams AE, Thomson RA, Schreiber GB, et al. Estimates of infectious disease risk factors in US blood donors. Retrovirus Epidemiology Donor Study. JAMA 1997; 277:967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26106/abstract/39\">",
"      Schreiber GB, Sharma UK, Glynn SA, et al. Evaluation of donors who give primarily for HIV testing (abstract). Transfusion 2001; 41(Supplement):35S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26106/abstract/40\">",
"      Tan L, Khan MK, Hawk JC 3rd. Use of blood therapeutically drawn from hemochromatosis patients. Council on Scientific Affairs, American Medical Association. Transfusion 1999; 39:1018.",
"     </a>",
"    </li>",
"    <li>",
"     21 CFR 640.120 (April, 2000).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26106/abstract/42\">",
"      Sanchez AM, Schreiber GB, Bethel J, et al. Prevalence, donation practices, and risk assessment of blood donors with hemochromatosis. JAMA 2001; 286:1475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26106/abstract/43\">",
"      Barton JC, Grindon AJ, Barton NH, Bertoli LF. Hemochromatosis probands as blood donors. Transfusion 1999; 39:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26106/abstract/44\">",
"      Barton JC, Preston BL, McDonnell SM, Rothenberg BE. Severity of iron overload in hemochromatosis: effect of volunteer blood donation before diagnosis. Transfusion 2001; 41:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26106/abstract/45\">",
"      Leitman SF, Browning JN, Yau YY, et al. Hemochromatosis subjects as allogeneic blood donors: a prospective study. Transfusion 2003; 43:1538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26106/abstract/46\">",
"      Mayo DJ, Rose AM, Matchett SE, et al. Screening potential blood donors at risk for human immunodeficiency virus. Transfusion 1991; 31:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26106/abstract/47\">",
"      Petersen LR, Lackritz E, Lewis WF, et al. The effectiveness of the confidential unit exclusion option. Transfusion 1994; 34:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26106/abstract/48\">",
"      Korelitz JJ, Williams AE, Busch MP, et al. Demographic characteristics and prevalence of serologic markers among donors who use the confidential unit exclusion process: the Retrovirus Epidemiology Donor Study. Transfusion 1994; 34:870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26106/abstract/49\">",
"      Pindyck J, Waldman A, Zang E, et al. Measures to decrease the risk of acquired immunodeficiency syndrome transmission by blood transfusion. Evidence of volunteer blood donor cooperation. Transfusion 1985; 25:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26106/abstract/50\">",
"      Zou S, Notari EP 4th, Musavi F, et al. Current impact of the confidential unit exclusion option. Transfusion 2004; 44:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26106/abstract/51\">",
"      Grossman BJ, Springer KM. Blood donor deferral registries: highlights of a conference. Transfusion 1992; 32:868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26106/abstract/52\">",
"      Casale G, Bignamini M, de Nicola P. Does blood donation prolong life expectancy? Vox Sang 1983; 45:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26106/abstract/53\">",
"      Salonen JT, Tuomainen TP, Salonen R, et al. Donation of blood is associated with reduced risk of myocardial infarction. The Kuopio Ischaemic Heart Disease Risk Factor Study. Am J Epidemiol 1998; 148:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26106/abstract/54\">",
"      Meyers DG, Jensen KC, Menitove JE. A historical cohort study of the effect of lowering body iron through blood donation on incident cardiac events. Transfusion 2002; 42:1135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26106/abstract/55\">",
"      Glynn SA, Kleinman SH, Schreiber GB, et al. Trends in incidence and prevalence of major transfusion-transmissible viral infections in US blood donors, 1991 to 1996. Retrovirus Epidemiology Donor Study (REDS). JAMA 2000; 284:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26106/abstract/56\">",
"      Edgren G, Tran TN, Hjalgrim H, et al. Improving health profile of blood donors as a consequence of transfusion safety efforts. Transfusion 2007; 47:2017.",
"     </a>",
"    </li>",
"    <li>",
"     Food and Drug Administration. Center for Biologics Evaluation and Research, Division of Inspections and Surveillance. Biological Product Deviation Reports-Annual-Summary for Fiscal year 2007.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26106/abstract/58\">",
"      Dunbar N, Katz J, Nambiar A. The potential impact of new donor height and weight criteria on young donor eligibility and faint or prefaint reaction rates. Transfusion 2011; 51:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26106/abstract/59\">",
"      Tomasulo PA, Anderson AJ, Paluso MB, et al. A study of criteria for blood donor deferral. Transfusion 1980; 20:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26106/abstract/60\">",
"      Yuan S, Gornbein J, Smeltzer B, et al. Risk factors for acute, moderate to severe donor reactions associated with multicomponent apheresis collections. Transfusion 2008; 48:1213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26106/abstract/61\">",
"      Eder AF, Dy BA, Kennedy JM, et al. Improved safety for young whole blood donors with new selection criteria for total estimated blood volume. Transfusion 2011; 51:1522.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.americasblood.org/go.cfm?do=page.view&amp;pid=13#age_limits (Accessed on January 14, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26106/abstract/63\">",
"      Pi DW, Krikler SH, Sparling TG, et al. Reappraisal of optimal hemoglobin standards for female blood donors in Canada. Transfusion 1994; 34:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26106/abstract/64\">",
"      Holland PV. Measuring the volume of packed RBCs in donors. Transfusion 2001; 41:309.",
"     </a>",
"    </li>",
"    <li>",
"     Standards for blood banks and transfusion services, 25th ed, Price TH (Ed), American Association of Blood Banks, Bethesda, MD 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26106/abstract/66\">",
"      Wood EM, Kim DM, Miller JP. Accuracy of predonation Hct sampling affects donor safety, eligibility, and deferral rates. Transfusion 2001; 41:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26106/abstract/67\">",
"      Mendrone A Jr, Sabino EC, Sampaio L, et al. Anemia screening in potential female blood donors: comparison of two different quantitative methods. Transfusion 2009; 49:662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26106/abstract/68\">",
"      Pottgiesser T, Specker W, Umhau M, et al. Recovery of hemoglobin mass after blood donation. Transfusion 2008; 48:1390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26106/abstract/69\">",
"      Gordeuk VR, Brittenham GM, Bravo J, et al. Prevention of iron deficiency with carbonyl iron in female blood donors. Transfusion 1990; 30:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26106/abstract/70\">",
"      Bianco C, Brittenham G, Gilcher RO, et al. Maintaining iron balance in women blood donors of childbearing age: summary of a workshop. Transfusion 2002; 42:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26106/abstract/71\">",
"      Bier-Ulrich AM, Haubelt H, Anders C, et al. The impact of intensive serial plasmapheresis and iron supplementation on iron metabolism and Hb concentration in menstruating women: a prospective randomized placebo-controlled double-blind study. Transfusion 2003; 43:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26106/abstract/72\">",
"      Mast AE, Foster TM, Pinder HL, et al. Behavioral, biochemical, and genetic analysis of iron metabolism in high-intensity blood donors. Transfusion 2008; 48:2197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26106/abstract/73\">",
"      Cable RG, Glynn SA, Kiss JE, et al. Iron deficiency in blood donors: analysis of enrollment data from the REDS-II Donor Iron Status Evaluation (RISE) study. Transfusion 2011; 51:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26106/abstract/74\">",
"      Radtke H, Tegtmeier J, R&ouml;cker L, et al. Daily doses of 20 mg of elemental iron compensate for iron loss in regular blood donors: a randomized, double-blind, placebo-controlled study. Transfusion 2004; 44:1427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26106/abstract/75\">",
"      Magnussen K, Bork N, Asmussen L. The effect of a standardized protocol for iron supplementation to blood donors low in hemoglobin concentration. Transfusion 2008; 48:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26106/abstract/76\">",
"      Maghsudlu M, Nasizadeh S, Toogeh GR, et al. Short-term ferrous sulfate supplementation in female blood donors. Transfusion 2008; 48:1192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26106/abstract/77\">",
"      Newman B. Iron depletion by whole-blood donation harms menstruating females: the current whole-blood-collection paradigm needs to be changed. Transfusion 2006; 46:1667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26106/abstract/78\">",
"      Brittenham GM. Iron deficiency in whole blood donors. Transfusion 2011; 51:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26106/abstract/79\">",
"      Benjamin RJ, Dy BA, Kennedy JM, et al. The relative safety of automated two-unit red blood cell procedures and manual whole-blood collection in young donors. Transfusion 2009; 49:1874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26106/abstract/80\">",
"      H&ouml;gler W, Mayer W, Messmer C, et al. Prolonged iron depletion after allogeneic 2-unit RBC apheresis. Transfusion 2001; 41:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26106/abstract/81\">",
"      Radtke H, Mayer B, R&ouml;cker L, et al. Iron supplementation and 2-unit red blood cell apheresis: a randomized, double-blind, placebo-controlled study. Transfusion 2004; 44:1463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26106/abstract/82\">",
"      O'Meara A, Infanti L, Stebler C, et al. The value of routine ferritin measurement in blood donors. Transfusion 2011; 51:2183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26106/abstract/83\">",
"      Pasricha SR, McQuilten ZK, Keller AJ, Wood EM. Hemoglobin and iron indices in nonanemic premenopausal blood donors predict future deferral from whole blood donation. Transfusion 2011; 51:2709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26106/abstract/84\">",
"      Mast AE, Lee TH, Schlumpf KS, et al. The impact of HFE mutations on haemoglobin and iron status in individuals experiencing repeated iron loss through blood donation*. Br J Haematol 2012; 156:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26106/abstract/85\">",
"      Stohlawetz P, Stiegler G, Jilma B, et al. Measurement of the levels of reticulated platelets after plateletpheresis to monitor activity of thrombopoiesis. Transfusion 1998; 38:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26106/abstract/86\">",
"      Strauss RG. Risks of clinically significant thrombocytopenia and/or lymphocytopenia in donors after multiple plateletpheresis collections. Transfusion 2008; 48:1274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26106/abstract/87\">",
"      Lazarus EF, Browning J, Norman J, et al. Sustained decreases in platelet count associated with multiple, regular plateletpheresis donations. Transfusion 2001; 41:756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26106/abstract/88\">",
"      Katz L, Palmer K, McDonnell E, Kabat A. Frequent plateletpheresis does not clinically significantly decrease platelet counts in donors. Transfusion 2007; 47:1601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26106/abstract/89\">",
"      Richa E, Krueger P, Burgstaler EA, et al. The effect of double- and triple-apheresis platelet product donation on apheresis donor platelet and white blood cell counts. Transfusion 2008; 48:1325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26106/abstract/90\">",
"      Bolan CD, Greer SE, Cecco SA, et al. Comprehensive analysis of citrate effects during plateletpheresis in normal donors. Transfusion 2001; 41:1165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26106/abstract/91\">",
"      Bolan CD, Cecco SA, Yau YY, et al. Randomized placebo-controlled study of oral calcium carbonate supplementation in plateletpheresis: II. Metabolic effects. Transfusion 2003; 43:1414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26106/abstract/92\">",
"      Laspina SJ, Browne MA, McSweeney EN, et al. QTc prolongation in apheresis platelet donors. Transfusion 2002; 42:899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26106/abstract/93\">",
"      Despotis GJ, Goodnough LT, Dynis M, et al. Adverse events in platelet apheresis donors: A multivariate analysis in a hospital-based program. Vox Sang 1999; 77:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26106/abstract/94\">",
"      Bolan CD, Wesley RA, Yau YY, et al. Randomized placebo-controlled study of oral calcium carbonate administration in plateletpheresis: I. Associations with donor symptoms. Transfusion 2003; 43:1403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26106/abstract/95\">",
"      Bolan CD, Cecco SA, Wesley RA, et al. Controlled study of citrate effects and response to i.v. calcium administration during allogeneic peripheral blood progenitor cell donation. Transfusion 2002; 42:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26106/abstract/96\">",
"      Kishimoto M, Ohto H, Shikama Y, et al. Treatment for the decline of ionized calcium levels during peripheral blood progenitor cell harvesting. Transfusion 2002; 42:1340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26106/abstract/97\">",
"      Buchta C, Macher M, Bieglmayer C, et al. Reduction of adverse citrate reactions during autologous large-volume PBPC apheresis by continuous infusion of calcium-gluconate. Transfusion 2003; 43:1615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26106/abstract/98\">",
"      Kuter DJ, Goodnough LT, Romo J, et al. Thrombopoietin therapy increases platelet yields in healthy platelet donors. Blood 2001; 98:1339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26106/abstract/99\">",
"      Goodnough LT, Kuter DJ, McCullough J, et al. Prophylactic platelet transfusions from healthy apheresis platelet donors undergoing treatment with thrombopoietin. Blood 2001; 98:1346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26106/abstract/100\">",
"      Vadhan-Raj S, Kavanagh JJ, Freedman RS, et al. Safety and efficacy of transfusions of autologous cryopreserved platelets derived from recombinant human thrombopoietin to support chemotherapy-associated severe thrombocytopenia: a randomised cross-over study. Lancet 2002; 359:2145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26106/abstract/101\">",
"      Newman BH, Pichette S, Pichette D, Dzaka E. Adverse effects in blood donors after whole-blood donation: a study of 1000 blood donors interviewed 3 weeks after whole-blood donation. Transfusion 2003; 43:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26106/abstract/102\">",
"      Eder AF, Dy BA, Kennedy JM, et al. The American Red Cross donor hemovigilance program: complications of blood donation reported in 2006. Transfusion 2008; 48:1809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26106/abstract/103\">",
"      Newman BH. Donor reactions and injuries from whole blood donation. Transfus Med Rev 1997; 11:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26106/abstract/104\">",
"      Tomita T, Takayanagi M, Kiwada K, et al. Vasovagal reactions in apheresis donors. Transfusion 2002; 42:1561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26106/abstract/105\">",
"      Wieling W, France CR, van Dijk N, et al. Physiologic strategies to prevent fainting responses during or after whole blood donation. Transfusion 2011; 51:2727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26106/abstract/106\">",
"      Trouern-Trend JJ, Cable RG, Badon SJ, et al. A case-controlled multicenter study of vasovagal reactions in blood donors: influence of sex, age, donation status, weight, blood pressure, and pulse. Transfusion 1999; 39:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26106/abstract/107\">",
"      Newman BH, Graves S. A study of 178 consecutive vasovagal syncopal reactions from the perspective of safety. Transfusion 2001; 41:1475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26106/abstract/108\">",
"      Newman BH. Vasovagal reactions in high school students: findings relative to race, risk factor synergism, female sex, and non-high school participants. Transfusion 2002; 42:1557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26106/abstract/109\">",
"      Newman BH, Siegfried BA, Buchanan LA. Donor reactions among African-American and Caucasian first-time whole-blood donors. Transfusion 2005; 45:1398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26106/abstract/110\">",
"      Eder AF, Hillyer CD, Dy BA, et al. Adverse reactions to allogeneic whole blood donation by 16- and 17-year-olds. JAMA 2008; 299:2279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26106/abstract/111\">",
"      Hanson SA, France CR. Predonation water ingestion attenuates negative reactions to blood donation. Transfusion 2004; 44:924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26106/abstract/112\">",
"      Ando S, Kawamura N, Matsumoto M, et al. Simple standing test predicts and water ingestion prevents vasovagal reaction in the high-risk blood donors. Transfusion 2009; 49:1630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26106/abstract/113\">",
"      Newman B, Tommolino E, Andreozzi C, et al. The effect of a 473-mL (16-oz) water drink on vasovagal donor reaction rates in high-school students. Transfusion 2007; 47:1524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26106/abstract/114\">",
"      Tomasulo P, Kamel H, Bravo M, et al. Interventions to reduce the vasovagal reaction rate in young whole blood donors. Transfusion 2011; 51:1511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/31/26106/abstract/115\">",
"      Hanson SA, France CR. Social support attenuates presyncopal reactions to blood donation. Transfusion 2009; 49:843.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7949 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-27.109.116.13-E03BC582ED-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_31_26106=[""].join("\n");
var outline_f25_31_26106=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12093587\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H57715582\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ESTABLISHMENT OF PROCEDURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      SPECIFIC DONOR SCREENING PROCEDURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Pre-donation screening",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Donor incentives",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Use of blood withdrawn for therapeutic purposes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Screening at the donation site",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Confidential unit exclusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Registry of deferred donors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Effect of screening procedures on overall donor health",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      POSTDONATION SCREENING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      PROTECTION OF THE DONOR AND DEFERRAL CRITERIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      General requirements",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H110596221\">",
"      - Estimated blood volume",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H110596228\">",
"      - Other requirements",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Detection of anemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Repeat blood donors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Apheresis red cell donors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Apheresis platelet donors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Citrate toxicity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Stimulation of thrombopoiesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Apheresis granulocyte donors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      COMPLICATIONS OF BLOOD DONATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Vasovagal syncope",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12093587\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/7949\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7949|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?30/59/31676\" title=\"table 1\">",
"      Infection risk of blood products",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/14/11498?source=related_link\">",
"      Blood donor medical history",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/39/26234?source=related_link\">",
"      Causes and diagnosis of anemia due to iron deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/61/21466?source=related_link\">",
"      Clinical applications of thrombopoietic growth factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/50/36646?source=related_link\">",
"      Clinical manifestations of hypocalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/31/6646?source=related_link\">",
"      Complications of therapeutic plasma exchange",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/18/4393?source=related_link\">",
"      Granulocyte transfusions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/41/40601?source=related_link\">",
"      Laboratory testing of donated blood",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?21/52/22338?source=related_link\">",
"      Patient information: Blood donation (giving blood) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?26/12/26820?source=related_link\">",
"      Patient information: Blood donation and transfusion (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/54/12134?source=related_link\">",
"      Preoperative autologous blood donation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/32/18952?source=related_link\">",
"      Treatment of hereditary hemochromatosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_31_26107="Diagnosis of anti poly def";
var content_f25_31_26107=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F77185&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=9\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F77185&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=9\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Classification of deficient response to pneumococcal vaccination",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"3\">",
"        Severity of deficiency",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        IgG anti-pneumococcal antibodies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\" colspan=\"2\">",
"        Post-immunization",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3\">",
"        2-5 years of age",
"       </td>",
"       <td class=\"subtitle3\">",
"        &ge;6 years of age",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Severe",
"       </td>",
"       <td>",
"        Protective antibody levels for &le; 2 serotypes",
"       </td>",
"       <td>",
"        Protective antibody levels for &le; 2 serotypes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Moderate",
"       </td>",
"       <td>",
"        Protective antibody levels for &lt;50% of serotypes administered",
"       </td>",
"       <td>",
"        Protective antibody levels for &lt;70% of serotypes administered",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    A protective antibody concentration is defined as &ge;1.3 micrograms/mL, based on response to polysaccharide vaccine serotypes in patients &gt;2 years of age.",
"    <br>",
"     If a patient previously received the conjugate pneumococcal vaccine and had protective titers to those serotypes, then an adequate response would be expected to the age-appropriate percentage (50% or 70%) of those serotypes exclusive to the polysaccharide vaccine.",
"     <div class=\"footnotes\">",
"      %: percent of polysaccharide vaccine serotypes administered and tested.",
"     </div>",
"     <div class=\"reference\">",
"      Adapted from Sorensen, RU, Moore, C. Peds Clin N A 2000; 42:1225.",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_31_26107=[""].join("\n");
var outline_f25_31_26107=null;
var title_f25_31_26108="Clin pulm infect score";
var content_f25_31_26108=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F77054&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F77054&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical Pulmonary Infection Score (CPIS)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Temperature",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &ge;36.5 or &le;38.4 = 0 point",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &ge;38.5 or &le;38.9 = 1 point",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &ge;39 or &lt;36.5 = 2 points",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Blood leukocytes, microL",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &ge;4000 or &le;11,000 = 0 points",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &lt;4000 or &gt;11,000 = 1 point",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Band forms &ge;50 percent = add 1 point",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Tracheal secretions",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Absence of tracheal secretions = 0 point",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Presence of non-purulent tracheal secretions = 1 point",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Presence of purulent tracheal secretions = 2 points",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Oxygenation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       PaO2/FIO2, mmHg &gt;240 or ARDS (defined as PaO2/FIO2 &le;200, PAWP &le;18 mmHg and acute bilateral infiltrates) = 0 points",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       PaO2/FIO2 &le;240 and no ARDS = 2 points",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Pulmonary radiography",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       No infiltrate = 0 point",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Diffuse (patchy) infiltrate = 1 point",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Localized infiltrate = 2 points",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Progression of pulmonary infiltrate",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       No radiographic progression = 0 point",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Radiographic progression (after HF and ARDS excluded) = 2 points",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Culture of tracheal aspirate",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Pathogenic bacteria cultured in rare or few quantities or no growth = 0 point",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Pathogenic bacteria cultured in moderate or heavy quantity = 1 point",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Same pathogenic bacteria seen on Gram's stain, add 1 point",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Total (a score of &gt;6 was considered suggestive of pneumonia)",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ARDS: acute respiratory distress syndrome; HF: heart failure; PAWP: pulmonary arterial wedge pressure.",
"     <br>",
"      An initial score is based upon the first five variables. The last two variables are assessed on day 2 or 3.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted with permission from: Singh, N, Rogers, P, Atwood, CW, et al. Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit: a proposed solution for indiscriminate antibiotic prescription. Am J Respir Crit Care Med 2000; 162:505. Copyright &copy; 2002 American Thoracic Society.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_31_26108=[""].join("\n");
var outline_f25_31_26108=null;
var title_f25_31_26109="Kallikrein kinin system";
var content_f25_31_26109=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F74570&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F74570&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Kallikrein-kinin system",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 224px; height: 174px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_31_26109=[""].join("\n");
var outline_f25_31_26109=null;
var title_f25_31_26110="Depression prevalence";
var content_f25_31_26110=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F71214&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F71214&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 555px\">",
"   <div class=\"ttl\">",
"    Prevalence of depressive disorders in various patient populations",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 535px; height: 368px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Prevalence range varies according to study.",
"    </div>",
"    <div class=\"reference\">",
"     Data from Birrer, RB, Vemuri, SP. Depression in later life: a diagnostic and therapeutic challenge. Am Fam Physician 2004; 69:2375",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_31_26110=[""].join("\n");
var outline_f25_31_26110=null;
var title_f25_31_26111="Locations transverse vag septa";
var content_f25_31_26111=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F53442&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F53442&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Schematic drawing of possible locations of a transverse vaginal septum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 278px; height: 386px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     <p>",
"      Reproduced with permission from: Laufer MR. Structural abnormalities of the female reproductive tract. In: Pediatric and adolescent gynecology, 6th ed, Emans SJ, Laufer MR, Goldstein DP (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins.",
"     </p>",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_31_26111=[""].join("\n");
var outline_f25_31_26111=null;
        